1
|
Kuboki Y, Fakih M, Strickler J, Yaeger R, Masuishi T, Kim EJ, Bestvina CM, Kopetz S, Falchook GS, Langer C, Krauss J, Puri S, Cardona P, Chan E, Varrieur T, Mukundan L, Anderson A, Tran Q, Hong DS. Sotorasib with panitumumab in chemotherapy-refractory KRAS G12C-mutated colorectal cancer: a phase 1b trial. Nat Med 2024; 30:265-270. [PMID: 38177853 DOI: 10.1038/s41591-023-02717-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Accepted: 11/14/2023] [Indexed: 01/06/2024]
Abstract
The current third-line (and beyond) treatment options for RAS-mutant metastatic colorectal cancer have yielded limited efficacy. At the time of study start, the combination of sotorasib, a KRAS (Kirsten rat sarcoma viral oncogene homolog)-G12C inhibitor, and panitumumab, an epidermal growth factor receptor (EGFR) inhibitor, was hypothesized to overcome treatment-induced resistance. This phase 1b substudy of the CodeBreaK 101 master protocol evaluated sotorasib plus panitumumab in patients with chemotherapy-refractory KRASG12C-mutated metastatic colorectal cancer. Here, we report the results in a dose-exploration cohort and a dose-expansion cohort. Patients received sotorasib (960 mg, once daily) plus panitumumab (6 mg kg-1, once every 2 weeks). The primary endpoints were safety and tolerability. Secondary endpoints included efficacy and pharmacokinetics. Exploratory biomarkers at baseline were assessed. Forty-eight patients (dose-exploration cohort, n = 8; dose-expansion cohort, n = 40) were treated. Treatment-related adverse events of any grade and grade ≥3 occurred in 45 (94%) and 13 (27%) patients, respectively. In the dose-expansion cohort, the confirmed objective response rate was 30.0% (95% confidence interval (CI) 16.6%, 46.5%). Median progression-free survival was 5.7 months (95% CI 4.2, 7.7 months). Median overall survival was 15.2 months (95% CI 12.5 months, not estimable). Prevalent genomic coalterations included APC (84%), TP53 (74%), SMAD4 (33%), PIK3CA (28%) and EGFR (26%). Sotorasib-panitumumab demonstrated acceptable safety with promising efficacy in chemotherapy-refractory KRASG12C-mutated metastatic colorectal cancer. ClinicalTrials.gov identifier: NCT04185883 .
Collapse
Affiliation(s)
| | - Marwan Fakih
- City of Hope Comprehensive Cancer Center, Duarte, CA, USA
| | | | - Rona Yaeger
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | - Edward J Kim
- UC Davis Comprehensive Cancer Center, Sacramento, CA, USA
| | | | - Scott Kopetz
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | | | - Corey Langer
- University of Pennsylvania, Philadelphia, PA, USA
| | | | - Sonam Puri
- Huntsman Cancer Institute, Salt Lake City, UT, USA
| | | | | | | | | | | | - Qui Tran
- Amgen Inc., Thousand Oaks, CA, USA
| | - David S Hong
- The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| |
Collapse
|
2
|
Leal T, Langer C. Tumor Treating Fields therapy in metastatic non-small-cell lung cancer - Authors' reply. Lancet Oncol 2023; 24:e454. [PMID: 38039996 DOI: 10.1016/s1470-2045(23)00584-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2023] [Revised: 11/07/2023] [Accepted: 11/08/2023] [Indexed: 12/03/2023]
Affiliation(s)
- Ticiana Leal
- Winship Cancer Institute at Emory University, Atlanta, GA 30322, USA.
| | - Corey Langer
- Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
3
|
Yegya-Raman N, Lee SH, Friedes C, Iocolano M, Kim KN, Duan L, Li B, Sun L, Cohen R, Cengel KA, Levin WP, Langer C, Aggarwal C, Ky B, O'Quinn RP, Zou W, Teo K, Deasy JO, Xiao Y, Feigenberg SJ. Association of Cardiac Dose with Cardiac Events and Survival for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) Treated with Concurrent Chemoradiotherapy (cCRT) in the Era of Immune Checkpoint Inhibitor (ICI) Consolidation. Int J Radiat Oncol Biol Phys 2023; 117:S169-S170. [PMID: 37784421 DOI: 10.1016/j.ijrobp.2023.06.272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) To assess the association of cardiac dose with post-cCRT cardiac events and survival among patients (pts) with LA-NSCLC after adoption of ICI consolidation, modern radiotherapy (RT) techniques, and data-driven cardiac constraints. MATERIALS/METHODS This single-institution, multi-site retrospective study included 335 pts with LA-NSCLC treated with definitive cCRT (60-70 Gy) from October 2017 to December 2021. Pts were evaluated for ICI consolidation. Cardiac dose constraints included heart volume receiving ≥50 Gy (V50) <25% and mean heart dose (MHD) <20 Gy. Heart, left anterior descending artery (LAD), and left ventricle were autocontoured, manually reviewed, and edited. 21 dosimetric parameters (mean dose, max dose, and min dose to the hottest x% volume [Dx%(Gy); x from 5-95 in 5% intervals]) for each were extracted, as well as LAD V15. Baseline cardiovascular disease (bCVD) was defined as heart failure (HF), coronary artery disease, peripheral vascular disease, or cerebrovascular disease. Primary endpoint was post-cCRT major adverse cardiac events (MACE), defined as acute coronary syndrome, HF hospitalization/urgent visit, coronary revascularization, or cardiac death. Secondary endpoints were grade ≥3 cardiac events (CTCAE v5.0), overall survival (OS), cancer specific mortality (CSM), and other cause mortality (OCM). Competing risk regression was used for MACE and grade ≥3 cardiac events, and Cox regression for OS, CSM, and OCM. RESULTS Median age was 68 years, 139 (41%) had bCVD, and 225 (67%) received consolidation ICI. Proton therapy was used in 117 (35%), intensity-modulated RT in 199 (59%), and 3D conformal RT in 19 (6%). Median MHD was 8.7 Gy (IQR 4.6-14.4) and median LAD V15 1.4% (IQR 0-22). Median follow-up was 39.5 months. 35 MACE events occurred; 1- and 2-year cumulative incidence (CI) were 4.2% and 9.5%. No cardiac dosimetric parameter associated with MACE after adjusting for bCVD and age (e.g., MHD sHR 0.98/Gy, 95% CI 0.93-1.03, p = 0.43) or within the following 3 subgroups: no bCVD, photon therapy, and ICI consolidation. 87 grade ≥3 cardiac events occurred; 1- and 2- year CI were 12.6% and 20.4%. Heart dose was not associated with grade ≥3 cardiac events after adjusting for bCVD, ECOG, and BMI (e.g., MHD sHR 1.00/Gy, 95% CI 0.97-1.03, p = 0.85) or within the 3 aforesaid subgroups. 183 OS events occurred, including 125 CSM and 58 OCM events. Multiple cardiac dosimetric parameters associated with worse OS on multivariable analysis (e.g., LAD V15 HR 1.01/%, 95% CI 1.00-1.02, p = 0.003), driven by associations with CSM (LAD V15 HR 1.02/%, p<0.001) but not OCM (LAD V15 HR 1.00/%, p = 0.73). Median OS was worse for LAD V15 ≥10% (22.2 vs 35.1 months, p = 0.004). CONCLUSION Among pts with LA-NSCLC treated with cCRT after adoption of ICI consolidation, modern RT techniques, and cardiac constraints, post-cCRT cardiac events were common but showed no association with cardiac dose. Cardiac dose associated with OS, driven by an association with CSM and not OCM, which may not reflect cardiac toxicity.
Collapse
Affiliation(s)
- N Yegya-Raman
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - S H Lee
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - C Friedes
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - M Iocolano
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - K N Kim
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - L Duan
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - B Li
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - L Sun
- Department of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
| | - R Cohen
- Department of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
| | - K A Cengel
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - W P Levin
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - C Langer
- Department of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
| | - C Aggarwal
- Department of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
| | - B Ky
- Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA
| | - R P O'Quinn
- Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA
| | - W Zou
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - K Teo
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - J O Deasy
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Y Xiao
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - S J Feigenberg
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
4
|
Iocolano M, Yegya-Raman N, Wang X, Friedes C, Lee SH, Duan L, Li B, Levin WP, Cengel KA, Langer C, Cohen R, Sun L, Aggarwal C, Doucette A, Xiao Y, Teo K, O'Reilly SE, Zou W, Simone CB, Feigenberg SJ. Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiotherapy (IMRT) for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) in the Era of Immune Checkpoint Inhibitor (ICI) Consolidation: A Retrospective Cohort Study. Int J Radiat Oncol Biol Phys 2023; 117:e26. [PMID: 37784996 DOI: 10.1016/j.ijrobp.2023.06.705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Patients (pts) with LA-NSCLC treated with concurrent chemoradiation (cCRT) and ICI consolidation are at high risk for treatment-related toxicities and subsequent hospitalization. We hypothesized that PBT is associated with a reduction in acute unplanned hospitalizations as compared to IMRT in the era of ICI consolidation. MATERIALS/METHODS This single institution, multi-site retrospective study included consecutive pts with LA-NSCLC treated with definitive cCRT with either PBT or IMRT from October 2017 to December 2021. Pts were evaluated for consolidative ICI. Primary endpoint was unplanned treatment-related hospitalization within 90 days of first radiation (RT) treatment. Secondary endpoints included grade 3+ pneumonitis, grade 3+ esophagitis, PFS and OS. Logistic regression was used to assess associations with 90-day hospitalization. Competing risk regression was used for grade 3+ pneumonitis and esophagitis, and Cox regression for PFS and OS. RESULTS A total of 316 pts were included: 117 (37%) received PBT and 199 (63%) IMRT. Median age was 68.5 yrs; median RT dose 66.6 Gy (IQR 65.9-70.0). PBT group was older (median 71.1 vs 67.2 yrs, p<0.005) and had a higher Charlson comorbidity index (CCI) (median 4 vs 3, p = 0.02). There was no significant difference in ECOG, smoking pack-years, T stage, N stage, target volume size, or receipt of ICI consolidation (66.7% vs 68.3%, p = 0.76). PBT group had lower mean heart dose (5.9 vs 10.8 Gy, p<0.001), LAD V15 (0 vs 6 %, p = 0.001), mean lung dose (14.7 vs 15.7 Gy, p <0.008) and effective dose to immune circulating cells (median 3.7 vs 4.9 Gy, p<0.001) but not mean esophagus dose. PBT was associated with fewer unplanned 90-day hospitalizations (23.9% vs 34.7%); which persisted on multivariable analysis (OR 0.52, 95% CI 0.30-0.90, p = 0.02) after adjusting for CCI, smoking pack-years, T4 tumors and target volume. Reasons for hospitalization in PBT and IMRT groups included progression (1.7% vs 1.5%), definite/probable toxicity from cCRT (11.1% vs 18.6%), possible toxicity from cCRT (7.7% vs 12.6%) or unrelated to cCRT (3.4% vs 2.0%). There was no significant difference between PBT or IMRT groups in G3+ pneumonitis (1-year 6.0% vs 9.1%, p = 0.49), G3+ esophagitis (1-year 6.0% vs 6.5%, p = 0.71), PFS (median 14.4 vs 15.1 months, p = 0.69), or OS (median 34.2 vs 29.4 months, p = 0.41). CONCLUSION Among pts with LA-NSCLC treated with cCRT in the era of ICI consolidation, PBT was associated with fewer acute unplanned hospitalizations compared to IMRT. There was no difference in G3+ pneumonitis, G3+ esophagitis, PFS or OS.
Collapse
Affiliation(s)
- M Iocolano
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - N Yegya-Raman
- Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - X Wang
- University of Pennsylvania, Department of Biostatistics and Epidemiology, Philadelphia, PA
| | - C Friedes
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - S H Lee
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - L Duan
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - B Li
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - W P Levin
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - K A Cengel
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - C Langer
- Department of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
| | - R Cohen
- Department of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
| | - L Sun
- Department of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
| | - C Aggarwal
- Department of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
| | - A Doucette
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - Y Xiao
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - K Teo
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - S E O'Reilly
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - W Zou
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | | | - S J Feigenberg
- Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
5
|
Friedes C, Yegya-Raman N, Iocolano M, Lee SH, Li B, Duan L, Levin WP, Cengel KA, Sun L, Aggarwal C, Marmarelis ME, Doucette A, Cohen R, Xiao Y, Langer C, Feigenberg SJ. Patterns of Failure, Volume of Disease Progression, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) Treated with Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors (ICI). Int J Radiat Oncol Biol Phys 2023; 117:e18-e19. [PMID: 37784800 DOI: 10.1016/j.ijrobp.2023.06.687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) For patients (pts) with LA-NSCLC treated with chemoradiation and consolidation ICI (CRT+ICI), the patterns of failure (POF) and volume of disease progression (PD) are not well characterized. The primary objective of this study was to classify POFs, the frequency of low volume relapse (LVR), and identify pts eligible for further ablative therapy. MATERIALS/METHODS We retrospectively identified pts with unresectable stage III NSCLC treated with CRT+ICI between October 2017 and December 2021 at a single institution. Site of first failure was classified as locoregional (LRF), distant (DF), or synchronous LRF + DF. Any LRF was subclassified as in field (IFF; PD within 90% isodose line), marginal (MF; within 50% isodose line) or out of field (OOF; outside of 50% isodose line). LVR was defined as < 3 discrete sites of PD in any number or location of organs. Pts with distant LVR were considered to have oligometastatic relapse. Ablative candidates were defined as pts with < 3 discrete sites of PD amenable to further RT or surgery. Cumulative incidence of PD was calculated with death as a competing risk. Progression free survival (PFS) and overall survival (OS) were calculated from the end of RT and assessed via Kaplan Meier. Multivariable Cox modeling was used to assess correlation of pt characteristics and time-to-event outcomes. Logistic regression was used to predict variables associated with LVR. RESULTS A total of 229 pts received CRT+ICI. Median follow up was 39 months and 119 pts experienced PD. Median PFS and OS were 18.4 and 34.5 months, respectively. Of pts with PD, 71 (60%) had DF, 28 (24%) had LRF+DF, and 20 (17%) had LRF. Of pts with any LRF, 28 (57%) had IFF, 10 (21%) had MF, and 10 (21%) had OOF. Estimated 1-year cumulative incidence of LRF, DF, and LRF+DF were 9.3% (95% CI 4.5-16), 39% (95% CI 31-48), and 19% (95% CI 12-27), respectively. A total of 63 (53%) pts had LVR. In pts with LVR, 19 (30%) had isolated thoracic relapse and 44 (69%) had oligometastatic relapse. Most oligometastatic disease was intracranial (22 metastases, 44%). Pts with LVR had a longer median OS vs pts with high volume relapse (37.4 vs 15.2 months, p<0.001). At time of PD, 56 (47%) pts were candidates for further ablative therapies. Subsequent anticancer therapies were local therapy alone (35%), local and systemic therapy (16%), systemic therapy alone (36%), or no therapy (13%). On multivariable analysis, LVR (HR 0.39; 95% CI 0.21-0.73, p = 0.003) and longer receipt of ICI (HR 0.96; 95% CI 0.95-0.98; p<0.001) were associated with improved survival while squamous histology (HR 2.26; 95% CI 1.18-4.32; p = 0.039) was associated with worse survival. Longer receipt of ICI was the only variable predictive for the development of LVR (OR 1.03; 95% CI 1.01-1.05; p = 0.004). CONCLUSION This is the largest real-world series reporting POF after CRT+ICI for stage III NSCLC. Approximately half of pts experience LVR and are candidates for further ablative therapy. Further data are needed to define optimal treatment strategies for pts with LVR after CRT+ICI.
Collapse
Affiliation(s)
- C Friedes
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - N Yegya-Raman
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - M Iocolano
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - S H Lee
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - B Li
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - L Duan
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - W P Levin
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - K A Cengel
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - L Sun
- Department of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
| | - C Aggarwal
- Department of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
| | - M E Marmarelis
- Department of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
| | - A Doucette
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - R Cohen
- Department of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
| | - Y Xiao
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - C Langer
- Department of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
| | - S J Feigenberg
- Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
6
|
Miller DG, Yegya-Raman N, Friedes C, Cengel KA, Plastaras JP, Simone Ii CB, Cohen R, Langer C, Feigenberg SJ, Butala AA. Pneumonitis after Palliative Thoracic Radiotherapy +/- Immunotherapy: A Retrospective Propensity-Matched Cohort Study. Int J Radiat Oncol Biol Phys 2023; 117:e138. [PMID: 37784706 DOI: 10.1016/j.ijrobp.2023.06.945] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Patients (pts) with advanced lung cancer often receive combined palliative thoracic radiotherapy (RT) and immune checkpoint inhibitors (ICI). There are limited data assessing the toxicities of combined ICI-RT in this setting. We sought to compare the rates of clinically significant pneumonitis among pts with lung cancer receiving palliative thoracic RT with or without recent or concomitant ICI. We hypothesized there would be a higher rate of grade 2+ pneumonitis among RT pts who received recent or concomitant ICI compared to those who did not. MATERIALS/METHODS We retrospectively identified consecutive pts with advanced/recurrent lung cancer from a tertiary academic center who received palliative thoracic RT with recent (defined as within 95 days of RT start) or concomitant ICI (ICI-RT group) between January 2014 and February 2020. Pts were propensity matched in a 1:1 manner (by age, sex, ECOG, RT modality, and RT dose) to lung cancer pts who received palliative thoracic RT without any history of ICI receipt (RT-only group). The presence and grade (CTCAE v5.0) of pneumonitis were independently assessed by two investigators. The primary endpoint was grade 2+ pneumonitis, estimated using the cumulative incidence function and compared between the ICI-RT and RT-only groups using Gray's test. The secondary endpoint was overall survival, estimated using the Kaplan-Meier method and compared between groups using the log-rank test. RESULTS A total of 146 pts were included in the study (73 in each group). There were no statistically significant differences between the ICI-RT and RT-only groups with respect to age (median 67.7 vs. 67.6, p = 0.97), sex (52% vs. 52% female, p = 1.00), pre-treatment ECOG 0-1 (74% vs 75%, p = 0.85), or biologically effective dose greater than 45 (48% vs. 48%, p = 1.00). The most common RT regimens were 30 Gy in 10 fractions (33 pts, 23%) and 20 Gy in 5 fractions (18 patients, 12%). A plurality of cases utilized 3DCRT (67 pts, 46%). In the ICI-RT group, the median time from last dose of ICI to the start of palliative RT was 16 days; three pts in this group-initiated ICI while receiving RT treatment. The most common ICI was pembrolizumab (36 pts, 49%). A total of eleven grade 2+ pneumonitis events (nine grade 2 and two grade 3 events) were observed. The ICI-RT group had a higher cumulative incidence of grade 2+ pneumonitis compared with the RT-only group (1-year rate, 12.3% vs. 2.7%, p = 0.029); grade 3 pneumonitis occurred in 1/73 (1.4%) in each group. There was no difference in overall survival between groups (median 239 vs. 218 days, p = 0.76). CONCLUSION In pts with advanced lung cancer treated with palliative thoracic RT, recent or concomitant ICI use was associated with a higher cumulative incidence of grade 2+ pneumonitis. However, the incidence of grade 3+ pneumonitis was low (1.4%) regardless of ICI receipt.
Collapse
Affiliation(s)
- D G Miller
- Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - N Yegya-Raman
- Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - C Friedes
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | - K A Cengel
- Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - J P Plastaras
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
| | | | - R Cohen
- Department of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
| | - C Langer
- Department of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
| | - S J Feigenberg
- Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| | - A A Butala
- Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
7
|
Leal T, Kotecha R, Ramlau R, Zhang L, Milanowski J, Cobo M, Roubec J, Petruzelka L, Havel L, Kalmadi S, Ward J, Andric Z, Berghmans T, Gerber DE, Kloecker G, Panikkar R, Aerts J, Delmonte A, Pless M, Greil R, Rolfo C, Akerley W, Eaton M, Iqbal M, Langer C. Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. Lancet Oncol 2023; 24:1002-1017. [PMID: 37657460 DOI: 10.1016/s1470-2045(23)00344-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Revised: 07/10/2023] [Accepted: 07/12/2023] [Indexed: 09/03/2023]
Abstract
BACKGROUND Tumor Treating Fields (TTFields) are electric fields that disrupt processes critical for cancer cell survival, leading to immunogenic cell death and enhanced antitumour immune response. In preclinical models of non-small-cell lung cancer, TTFields amplified the effects of chemotherapy and immune checkpoint inhibitors. We report primary results from a pivotal study of TTFields therapy in metastatic non-small-cell lung cancer. METHODS This randomised, open-label, pivotal phase 3 study recruited patients at 130 sites in 19 countries. Participants were aged 22 years or older with metastatic non-small-cell lung cancer progressing on or after platinum-based therapy, with squamous or non-squamous histology and ECOG performance status of 2 or less. Previous platinum-based therapy was required, but no restriction was placed on the number or type of previous lines of systemic therapy. Participants were randomly assigned (1:1) to TTFields therapy and standard systemic therapy (investigator's choice of immune checkpoint inhibitor [nivolumab, pembrolizumab, or atezolizumab] or docetaxel) or standard therapy alone. Randomisation was performed centrally using variable blocked randomisation and an interactive voice-web response system, and was stratified by tumour histology, treatment, and region. Systemic therapies were dosed according to local practice guidelines. TTFields therapy (150 kHz) was delivered continuously to the thoracic region with the recommendation to achieve an average of at least 18 h/day device usage. The primary endpoint was overall survival in the intention-to-treat population. The safety population included all patients who received any study therapy and were analysed according to the actual treatment received. The study is registered with ClinicalTrials.gov, NCT02973789. FINDINGS Between Feb 13, 2017, and Nov 19, 2021, 276 patients were enrolled and randomly assigned to receive TTFields therapy with standard therapy (n=137) or standard therapy alone (n=139). The median age was 64 years (IQR 59-70), 178 (64%) were male and 98 (36%) were female, 156 (57%) had non-squamous non-small-cell lung cancer, and 87 (32%) had received a previous immune checkpoint inhibitor. Median follow-up was 10·6 months (IQR 6·1-33·7) for patients receiving TTFields therapy with standard therapy, and 9·5 months (0·1-32·1) for patients receiving standard therapy. Overall survival was significantly longer with TTFields therapy and standard therapy than with standard therapy alone (median 13·2 months [95% CI 10·3-15·5] vs 9·9 months [8·1-11·5]; hazard ratio [HR] 0·74 [95% CI 0·56-0·98]; p=0·035). In the safety population (n=267), serious adverse events of any cause were reported in 70 (53%) of 133 patients receiving TTFields therapy plus standard therapy and 51 (38%) of 134 patients receiving standard therapy alone. The most frequent grade 3-4 adverse events were leukopenia (37 [14%] of 267), pneumonia (28 [10%]), and anaemia (21 [8%]). TTFields therapy-related adverse events were reported in 95 (71%) of 133 patients; these were mostly (81 [85%]) grade 1-2 skin and subcutaneous tissue disorders. There were three deaths related to standard therapy (two due to infections and one due to pulmonary haemorrhage) and no deaths related to TTFields therapy. INTERPRETATION TTFields therapy added to standard therapy significantly improved overall survival compared with standard therapy alone in metastatic non-small-cell lung cancer after progression on platinum-based therapy without exacerbating systemic toxicities. These data suggest that TTFields therapy is efficacious in metastatic non-small-cell lung cancer and should be considered as a treatment option to manage the disease in this setting. FUNDING Novocure.
Collapse
Affiliation(s)
- Ticiana Leal
- Winship Cancer Institute at Emory University, Atlanta, GA, USA.
| | - Rupesh Kotecha
- Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA
| | - Rodryg Ramlau
- Poznan University of Medical Sciences, Poznan, Poland
| | - Li Zhang
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China
| | | | - Manuel Cobo
- Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain
| | - Jaromir Roubec
- Nemocnice AGEL Ostrava-Vítkovice, Ostrava, Czech Republic
| | | | | | | | - Jeffrey Ward
- Washington University School of Medicine, St Louis, MO, USA
| | - Zoran Andric
- University Clinical Hospital Centre Bezanijska Kosa, Belgrade, Serbia
| | - Thierry Berghmans
- Jules Bordet Institute, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium
| | - David E Gerber
- Harold C Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | | | | | - Joachim Aerts
- Department of Pulmonary Medicine, The Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Angelo Delmonte
- IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori (IRST), Meldola, Italy
| | - Miklos Pless
- Kantonsspital Winterthur, Winterthur, Switzerland
| | - Richard Greil
- Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Salzburg, Austria; Paracelsus Medical University Salzburg, Salzburg, Austria; Cancer Cluster, Salzburg, Austria
| | - Christian Rolfo
- Center for Thoracic Oncology, Tisch Cancer Institute at Icahn School of Medicine, Mount Sinai, New York, NY, USA
| | - Wallace Akerley
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
| | | | - Mussawar Iqbal
- College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada
| | - Corey Langer
- Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
8
|
Bou-Samra P, Chang A, Azari F, Kennedy G, Segil A, Guo E, Marmarelis M, Langer C, Singhal S. Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: A review of the National Cancer Database. Cancer Med 2023. [PMID: 37062067 DOI: 10.1002/cam4.5915] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Revised: 03/09/2023] [Accepted: 03/27/2023] [Indexed: 04/17/2023] Open
Abstract
BACKGROUND Malignant pleural mesothelioma (MPM) is an aggressive cancer of the cells lining the pleural cavity with a low overall incidence. The National Cancer Database (NCDB) released in August 2022 updated data that reflect the newest trends in MPM. METHODS The NCDB was queried for patients diagnosed with MPM between 2004 and 2020. Variables collected included demographics, tumor characteristics, and treatment. Student's t-test and independent-samples proportions test were used for means analysis. Survival was assessed by the Kaplan-Meier method using SPSS version 28. RESULTS A total of 41,074 patients were diagnosed with mesothelioma, with a steady incidence (0.25%) between 2004 and 2017. The mean age of diagnosis was 70 (SD 13). 73.2% of the patients were males, 69% had no comorbidities, and 93.3% were white. More patients were diagnosed at Stage 1 after 2008 (p < 0.001). Since 2010, there has been a significant increase in patients offered treatment with 73.9% receiving some therapy (p < 0.01): 50.5% received chemotherapy, 27.6% surgery, 8.6% radiation, and 5.4% immunotherapy. The median overall survival was 10.3 months from diagnosis [95% CI: 10.2-10.5]. Risk factors associated with 30-day mortality from surgical intervention included age (OR = 1.02, p < 0.001), male gender (OR = 1.3, p = 0.03), poorly differentiated grade (OR = 2.1, p < 0.001), Stage 4 (OR = 1.4, p = 0014), and epithelioid histology (OR = 0.51, p = 0.03). CONCLUSION The current management of MPM is based on stage and histologic subtype. Due to the small numbers of patients at most academic centers, the NCDB provides a robust dataset to draw upon broad data points in treatment discussions with patients.
Collapse
Affiliation(s)
- Patrick Bou-Samra
- University of Pennsylvania Perelman School of Medicine, Pennsylvania, Philadelphia, USA
- Department of Thoracic Surgery, University of Pennsylvania Perelman School of Medicine, Pennsylvania, Philadelphia, USA
| | - Austin Chang
- University of Pennsylvania Perelman School of Medicine, Pennsylvania, Philadelphia, USA
- Department of Thoracic Surgery, University of Pennsylvania Perelman School of Medicine, Pennsylvania, Philadelphia, USA
| | - Feredun Azari
- University of Pennsylvania Perelman School of Medicine, Pennsylvania, Philadelphia, USA
- Department of Thoracic Surgery, University of Pennsylvania Perelman School of Medicine, Pennsylvania, Philadelphia, USA
| | - Gregory Kennedy
- University of Pennsylvania Perelman School of Medicine, Pennsylvania, Philadelphia, USA
- Department of Thoracic Surgery, University of Pennsylvania Perelman School of Medicine, Pennsylvania, Philadelphia, USA
| | - Alix Segil
- University of Pennsylvania Perelman School of Medicine, Pennsylvania, Philadelphia, USA
- Department of Thoracic Surgery, University of Pennsylvania Perelman School of Medicine, Pennsylvania, Philadelphia, USA
| | - Emily Guo
- University of Pennsylvania Perelman School of Medicine, Pennsylvania, Philadelphia, USA
- Department of Thoracic Surgery, University of Pennsylvania Perelman School of Medicine, Pennsylvania, Philadelphia, USA
| | - Melina Marmarelis
- University of Pennsylvania Perelman School of Medicine, Pennsylvania, Philadelphia, USA
- Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Pennsylvania, Philadelphia, USA
| | - Corey Langer
- University of Pennsylvania Perelman School of Medicine, Pennsylvania, Philadelphia, USA
- Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Pennsylvania, Philadelphia, USA
| | - Sunil Singhal
- University of Pennsylvania Perelman School of Medicine, Pennsylvania, Philadelphia, USA
- Department of Thoracic Surgery, University of Pennsylvania Perelman School of Medicine, Pennsylvania, Philadelphia, USA
| |
Collapse
|
9
|
Natarajan J, Yegya-Raman N, Kegelman TP, Kallan MJ, Roshkovan L, Katz S, Ky B, Fradley M, Xiao Y, Lee SH, Zhang Z, Langer C, Aggarwal C, Cohen R, Cengel K, Levin W, Berman AT, Feigenberg SJ. Cardiovascular Substructure Dose and Cardiac Events following Proton- and Photon-Based Chemoradiotherapy for Non-Small Cell Lung Cancer. Adv Radiat Oncol 2023. [DOI: 10.1016/j.adro.2023.101235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/08/2023] Open
|
10
|
Kim KN, Heintz J, Yegya-Raman N, Cohen R, Kegelman T, Cengel K, Marmarelis M, Sun L, Langer C, Aggarwal C, Singh A, Singhal S, Kucharczuk J, Robinson K, Feigenberg S. Toxicities and Deaths From Intercurrent Disease Following Contemporary Postoperative Radiotherapy in Resected Non-Small-Cell Lung Cancer. Clin Lung Cancer 2023; 24:e78-e86. [PMID: 36628846 DOI: 10.1016/j.cllc.2022.12.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2022] [Revised: 12/04/2022] [Accepted: 12/16/2022] [Indexed: 12/26/2022]
Abstract
INTRODUCTION The role of postoperative radiotherapy (PORT) in patients with resected locally advanced non-small-cell lung cancer (NSCLC) remains controversial due to the radiation techniques used in randomized trials. We conducted a retrospective cohort study evaluating contemporary PORT techniques to evaluate the safety of PORT and risk of death from intercurrent disease . MATERIALS AND METHODS We analyzed consecutive patients with NSCLC treated in a single center that underwent PORT for pN2 disease and/or positive margin, with 3-dimensional conformal radiotherapy (3DRT), intensity modulated radiotherapy , or proton RT (PRT), between 2008 and 2019. Clinical details were collected including intercurrent deaths, defined as death without cancer recurrence. Kaplan-Meier and Cox-Proportional Hazards Models were used. RESULTS Of 119 patients, 21 (17.6%) received 3DRT, 47 (39.5%) intensity modulated radiotherapy, and 51 (42.9%) PRT. Median follow-up was 40 months (range 8-136) and median RT dose was 5040cGy. Most patients (65.5%) received sequential adjuvant chemoRT; 18.5% received concurrent chemoRT. The rate of grade 3 toxicities was 9.2%. There were 13 (10.9%) deaths from intercurrent diseases, including 6 from second primary cancers and 2 from cardiopulmonary diseases. There were 2 additional deaths from cardiopulmonary disease in patients with cancer progression at time of death. Mean, V5Gy, V30Gy heart doses and mean lung doses were significantly lower with PRT. Three-year OS and disease-free-survival were 70.1% and 49.9%. CONCLUSION PORT using contemporary techniques was well tolerated with acceptable toxicity and low rates of intercurrent deaths. Proton therapy significantly reduced heart and lung doses, but radiotherapy modality was not associated with differences in intercurrent disease.
Collapse
Affiliation(s)
- Kristine N Kim
- Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
| | - Jonathan Heintz
- Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Nikhil Yegya-Raman
- Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Roger Cohen
- Division of Hematology Oncology, Department of Internal Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Timothy Kegelman
- Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Keith Cengel
- Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Melina Marmarelis
- Division of Hematology Oncology, Department of Internal Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Lova Sun
- Division of Hematology Oncology, Department of Internal Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Corey Langer
- Division of Hematology Oncology, Department of Internal Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Charu Aggarwal
- Division of Hematology Oncology, Department of Internal Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Aditi Singh
- Division of Hematology Oncology, Department of Internal Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Sunil Singhal
- Division of Thoracic Surgery, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - John Kucharczuk
- Division of Thoracic Surgery, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Kyle Robinson
- Division of Hematology Oncology, Department of Internal Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| | - Steven Feigenberg
- Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
| |
Collapse
|
11
|
Vannier C, Martens U, Bleckmann A, Zaiss M, Burkhart N, Decker T, Kaldune S, Langer C, Looß M, Hillebrand L, Vahtrik O, Frank M, Niemeier B, Potthoff K, Kasenda B. 67P Molecular testing and treatment of patients with advanced solid tumors harboring an NTRK gene fusion: Interim results of the REALTRK registry. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.100925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/11/2023] Open
|
12
|
Yegya-Raman N, Kegelman T, Lee S, Kim K, Natarajan J, Kallan M, Levin W, Cengel K, Kao G, Langer C, Cohen R, Aggarwal C, Singh A, Adusumalli S, O'Quinn R, Ky B, Apte A, Deasy J, Xiao Y, Feigenberg S. Association Between Cardiovascular Substructure Dose and Death Without Progression after Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
13
|
Langer C, von der Heyde E, Hahn D, Kubuschok B, Bockmühl U, Mueller-Huesmann H, Klautke G, von der Grün J, Beutner D, Büntzel J, Busch CJ, Tamaskovics B, Riera Knorrenschild J, Gutsche K, Welslau M, Gauler T, Waldenberger D, Dietz A. 680P HANNA: Real-world data of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), including first-line population, treated with nivolumab in Germany. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
14
|
Plank F, Beyer C, Langer C, Senoner T, Bleckwenn S, Widmann G, Barbieri F, Friedrich G, Dichtl W, Feuchtner G. The atherosclerosis profile by coronary CTA compared to the coronary artery calcium score (CACS) in a young symptomatic high-risk population between 19 and 49 years. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Whether the coronary artery calcium score (CACS) or coronary CTA should be used in young high-risk adults for screening of coronary artery disease (CAD), is an open debate and data sparse.
Aims
To evaluate the coronary atherosclerosis profile by coronary computed tomography angiography (CTA) in a young symptomatic high-risk population (age, 19–49 years) in comparison with the coronary artery calcium score (CACS).
Methods and results
1137 symptomatic high-risk patients between 19–49 years (mean 42.4y; 33.2%females) with suspected CAD who underwent CTA and CACS were assigned into 6 age groups (19–30; 31–35; 36–40; 41–45; 46–47; 48–49y).CTA-analysis included stenosis severity (CADRADS) and high-risk-plaque (“HRP”) criteria.
Atherosclerosis was more often detected by CTA than by CACS (45% vs. 27%; p<0.001), >50% stenosis in 13.6% and HRP in 17.7%. Prevalence of atherosclerosis was low and not different between CACS and CTA in the youngest (19–30y:5.2% and 6.4%; 30–35y:10.6% and 16%). Above >35 years, atherosclerosis detection by CTA increased (p=0.004, OR: 2.8, 95% CI: 1.45–5.89); and was higher by CTA as compared to CACS (34.9% vs 16.7%; p<0.001).
CTA outperformed CACS among all higher age groups >35 years, with an increasing gap towards a superior performance of CTA along with age: Above 35 years, stenosis severity (CADRADS) (p=0.002) and >50% stenosis increased from 2.6% to 12.5% (p<0.001).
The rate of HRP increased linearly with age from 6.4% to 26.5%.The distribution of HRP into CACS0 and CACS>0.1AU was similar among all age groups (CACS 0:45.1% had HRP), with an increasing proportion of HRP in CACS>0.1AU with age. 24.9% of CACS 0 patients had CAD by CTA, 4.4% >50% stenosis and 11.5% HRP.
Conclusion
Above 35 years of age, CTA outperforms CACS with an increasing power. Between 19 and 35 years, CACS 0 does not reliably rule out CAD and high-risk-plaque; hence for “noRISK100%safety”, CTA is superior.(#eachlifematters)
Funding Acknowledgement
Type of funding sources: None. 30 YOM diabetic, CACS 0 and HRP by CTAAtherosclerosis vs age: CACS vs CTA
Collapse
Affiliation(s)
- F Plank
- Innsbruck Medical University, Innsbruck, Austria
| | - C Beyer
- Innsbruck Medical University, Innsbruck, Austria
| | - C Langer
- Innsbruck Medical University, Innsbruck, Austria
| | - T Senoner
- Innsbruck Medical University, Innsbruck, Austria
| | - S Bleckwenn
- Innsbruck Medical University, Innsbruck, Austria
| | - G Widmann
- Innsbruck Medical University, Innsbruck, Austria
| | - F Barbieri
- Innsbruck Medical University, Innsbruck, Austria
| | - G Friedrich
- Innsbruck Medical University, Innsbruck, Austria
| | - W Dichtl
- Innsbruck Medical University, Innsbruck, Austria
| | - G Feuchtner
- Innsbruck Medical University, Innsbruck, Austria
| |
Collapse
|
15
|
Yegya-Raman N, Kegelman T, Kim K, Kallan M, Levin W, Cengel K, Langer C, Cohen R, Aggarwal C, Singh A, Bauml J, Adusumalli S, Denduluri S, O'Quinn R, Ky B, Berman A, Feigenberg S. MA06.01 Death From Intercurrent Disease After Proton- Versus Photon-Based Chemoradiotherapy for Non-Small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
16
|
Müller-Huesmann H, von der Heyde E, Hahn D, Langer C, Kubuschok B, Bockmühl U, Klautke G, Mauz PS, Reuter B, Beutner D, Büntzel J, von der Grün J, Busch CJ, Tamaskovics B, Riera-Knorrenschild J, Gutsche K, Welslau M, Gauler T, Waldenberger D, Dietz A. 924P HANNA: Effectiveness and quality-of-life data from a real-world study of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab in Germany. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
17
|
Garassino MC, Paz-Ares L, Hui R, Faivre-Finn C, Spira A, Planchard D, Özgüroğlu M, Daniel D, Vicente D, Murakami S, Langer C, Senan S, Spigel D, Rydén A, Zhang Y, O'Brien C, Dennis PA, Antonia SJ. Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. Future Oncol 2021; 17:1165-1184. [PMID: 33583206 DOI: 10.2217/fon-2020-1102] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Aim: We retrospectively investigated the impact of tumor PD-L1 expression and prior chemoradiotherapy (CRT)-related variables on patient-reported outcomes (PROs) from PACIFIC. Patients & methods: PACIFIC was a Phase III study of durvalumab versus placebo after CRT in patients with unresectable, stage III non-small-cell lung cancer. If available, pre-CRT tumor tissue was tested for PD-L1 tumor-cell expression, scored at prespecified (25%) and post-hoc (1%) cut-offs. PROs were assessed using EORTC QLQ C30/-LC13. Results: Similar to the intent-to-treat (ITT) population, most PROs remained stable over time across PD-L1 and CRT subgroups, with few clinically relevant differences between treatment arms. Time to deterioration was generally similar to the ITT population. Conclusion: Neither PD-L1 expression nor prior CRT-related variables influenced PROs with durvalumab therapy. Clinical trial registration: NCT02125461 (ClinicalTrials.gov).
Collapse
Affiliation(s)
| | - Luis Paz-Ares
- Hospital Universitario 12 de Octubre, CiberOnc, Universidad Complutense & CNIO, Madrid, 28041, Spain
| | - Rina Hui
- Westmead Hospital & the University of Sydney, Sydney, NSW, 2145, Australia
| | - Corinne Faivre-Finn
- The University of Manchester & The Christie NHS Foundation Trust, Manchester, M20 4BX, UK
| | - Alex Spira
- Virginia Cancer Specialists Research Institute, Fairfax, VA, & US Oncology Research, The Woodlands, TX 22031, USA
| | - David Planchard
- Institut Gustave Roussy, Department of Medical Oncology, Thoracic Group, Villejuif, 94805, France
| | - Mustafa Özgüroğlu
- Istanbul University - Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, 34320, Turkey
| | - Davey Daniel
- Sarah Cannon Research Institute/Tennessee Oncology, Chattanooga, TN 37203, USA
| | - David Vicente
- Hospital Universitario Virgen Macarena, Seville, 41009, Spain
| | | | - Corey Langer
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Suresh Senan
- Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, 1081, The Netherlands
| | - David Spigel
- Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN 3720231, USA
| | | | | | | | | | - Scott J Antonia
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
| |
Collapse
|
18
|
Predina JD, Haas AR, Martinez M, O'Brien S, Moon EK, Woodruff P, Stadanlick J, Corbett C, Frenzel-Sulyok L, Bryski MG, Eruslanov E, Deshpande C, Langer C, Aguilar LK, Guzik BW, Manzanera AG, Aguilar-Cordova E, Singhal S, Albelda SM. Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity. Mol Ther 2021; 29:658-670. [PMID: 33160076 PMCID: PMC7854297 DOI: 10.1016/j.ymthe.2020.11.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2020] [Revised: 10/01/2020] [Accepted: 10/31/2020] [Indexed: 11/28/2022] Open
Abstract
Gene-mediated cytotoxic immunotherapy (GMCI) is an immuno-oncology approach involving local delivery of a replication-deficient adenovirus expressing herpes simplex thymidine kinase (AdV-tk) followed by anti-herpetic prodrug activation that promotes immunogenic tumor cell death, antigen-presenting cell activation, and T cell stimulation. This phase I dose-escalation pilot trial assessed bronchoscopic delivery of AdV-tk in patients with suspected lung cancer who were candidates for surgery. A single intra-tumoral AdV-tk injection in three dose cohorts (maximum 1012 viral particles) was performed during diagnostic staging, followed by a 14-day course of the prodrug valacyclovir, and subsequent surgery 1 week later. Twelve patients participated after appropriate informed consent. Vector-related adverse events were minimal. Immune biomarkers were evaluated in tumor and blood before and after GMCI. Significantly increased infiltration of CD8+ T cells was found in resected tumors. Expression of activation, inhibitory, and proliferation markers, such as human leukocyte antigen (HLA)-DR, CD38, Ki67, PD-1, CD39, and CTLA-4, were significantly increased in both the tumor and peripheral CD8+ T cells. Thus, intratumoral AdV-tk injection into non-small-cell lung cancer (NSCLC) proved safe and feasible, and it effectively induced CD8+ T cell activation. These data provide a foundation for additional clinical trials of GMCI for lung cancer patients with potential benefit if combined with other immune therapies.
Collapse
Affiliation(s)
- Jarrod D Predina
- Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Andrew R Haas
- Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Pulmonary, Allergy and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Marina Martinez
- Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Pulmonary, Allergy and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Shaun O'Brien
- Division of Pulmonary, Allergy and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Edmund K Moon
- Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Pulmonary, Allergy and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Patrick Woodruff
- Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Pulmonary, Allergy and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Jason Stadanlick
- Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Christopher Corbett
- Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Lydia Frenzel-Sulyok
- Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Mitchell G Bryski
- Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Evgeniy Eruslanov
- Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Charuhas Deshpande
- Pulmonary and Mediastinal Pathology, Department of Clinical Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Corey Langer
- Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, MA, USA
| | - Laura K Aguilar
- Advantagene, Inc. d.b.a. Candel Therapeutics, Needham, MA, USA
| | - Brian W Guzik
- Advantagene, Inc. d.b.a. Candel Therapeutics, Needham, MA, USA
| | | | | | - Sunil Singhal
- Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Steven M Albelda
- Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Pulmonary, Allergy and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
| |
Collapse
|
19
|
Ong WJ, Brown EF, Browne J, Ahn S, Childers K, Crider BP, Dombos AC, Gupta SS, Hitt GW, Langer C, Lewis R, Liddick SN, Lyons S, Meisel Z, Möller P, Montes F, Naqvi F, Pereira J, Prokop C, Richman D, Schatz H, Schmidt K, Spyrou A. β Decay of ^{61}V and its Role in Cooling Accreted Neutron Star Crusts. Phys Rev Lett 2020; 125:262701. [PMID: 33449748 DOI: 10.1103/physrevlett.125.262701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2019] [Accepted: 11/18/2020] [Indexed: 06/12/2023]
Abstract
The interpretation of observations of cooling neutron star crusts in quasipersistent x-ray transients is affected by predictions of the strength of neutrino cooling via crust Urca processes. The strength of crust Urca neutrino cooling depends sensitively on the electron-capture and β-decay ground-state-to-ground-state transition strengths of neutron-rich rare isotopes. Nuclei with a mass number of A=61 are predicted to be among the most abundant in accreted crusts, and the last remaining experimentally undetermined ground-state-to-ground-state transition strength was the β decay of ^{61}V. This Letter reports the first experimental determination of this transition strength, a ground-state branching of 8.1_{-3.1}^{+4.0}%, corresponding to a log ft value of 5.5_{-0.2}^{+0.2}. This result was achieved through the measurement of the β-delayed γ rays using the total absorption spectrometer SuN and the measurement of the β-delayed neutron branch using the neutron long counter system NERO at the National Superconducting Cyclotron Laboratory at Michigan State University. This method helps to mitigate the impact of the pandemonium effect in extremely neutron-rich nuclei on experimental results. The result implies that A=61 nuclei do not provide the strongest cooling in accreted neutron star crusts as expected by some predictions, but that their cooling is still larger compared to most other mass numbers. Only nuclei with mass numbers 31, 33, and 55 are predicted to be cooling more strongly. However, the theoretical predictions for the transition strengths of these nuclei are not consistently accurate enough to draw conclusions on crust cooling. With the experimental approach developed in this work, all relevant transitions are within reach to be studied in the future.
Collapse
Affiliation(s)
- W-J Ong
- Nuclear and Chemical Sciences Division, Lawrence Livermore National Laboratory, Livermore, California 94550, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
- National Superconducting Cyclotron Laboratory, East Lansing, Michigan 48824, USA
| | - E F Brown
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
- National Superconducting Cyclotron Laboratory, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics-Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Computational Mathematics, Science, and Engineering, Michigan State University, East Lansing, Michigan 48824, USA
| | - J Browne
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
- National Superconducting Cyclotron Laboratory, East Lansing, Michigan 48824, USA
| | - S Ahn
- Joint Institute for Nuclear Astrophysics-Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Cylotron Institute, Texas A&M University, College Station, Texas 77843, USA
| | - K Childers
- National Superconducting Cyclotron Laboratory, East Lansing, Michigan 48824, USA
- Department of Chemistry, Michigan State University, East Lansing, Michigan 48824, USA
| | - B P Crider
- Department of Physics and Astronomy, Mississippi State University, Mississippi State, Mississippi 39762, USA
| | - A C Dombos
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
- National Superconducting Cyclotron Laboratory, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics-Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
| | - S S Gupta
- Indian Institute of Technology Ropar, Nangal Road, Rupnagar (Ropar), Punjab 140 001, India
| | - G W Hitt
- Department of Physics and Engineering Science, Coastal Carolina University, Conway, South Carolina 29528, USA
| | - C Langer
- Institute for Applied Physics, Goethe-University Frankfurt a. M., Frankfurt am Main 60438, Germany
| | - R Lewis
- National Superconducting Cyclotron Laboratory, East Lansing, Michigan 48824, USA
- Department of Chemistry, Michigan State University, East Lansing, Michigan 48824, USA
| | - S N Liddick
- National Superconducting Cyclotron Laboratory, East Lansing, Michigan 48824, USA
- Department of Chemistry, Michigan State University, East Lansing, Michigan 48824, USA
| | - S Lyons
- National Superconducting Cyclotron Laboratory, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics-Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
| | - Z Meisel
- Joint Institute for Nuclear Astrophysics-Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Ohio Univeristy, Athens, Ohio 45701, USA
| | - P Möller
- Joint Institute for Nuclear Astrophysics-Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - F Montes
- National Superconducting Cyclotron Laboratory, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics-Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
| | - F Naqvi
- National Superconducting Cyclotron Laboratory, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics-Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics & Astrophysics, University of Delhi, Delhi 110007, India
| | - J Pereira
- National Superconducting Cyclotron Laboratory, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics-Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
| | - C Prokop
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - D Richman
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - H Schatz
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
- National Superconducting Cyclotron Laboratory, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics-Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
| | - K Schmidt
- National Superconducting Cyclotron Laboratory, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics-Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
| | - A Spyrou
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
- National Superconducting Cyclotron Laboratory, East Lansing, Michigan 48824, USA
- Joint Institute for Nuclear Astrophysics-Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
| |
Collapse
|
20
|
Faivre-Finn C, Spigel DR, Senan S, Langer C, Perez BA, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz-Ares L, Broadhurst H, Wadsworth C, Dennis PA, Antonia SJ. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Lung Cancer 2020; 151:30-38. [PMID: 33285469 DOI: 10.1016/j.lungcan.2020.11.024] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2020] [Revised: 09/29/2020] [Accepted: 11/23/2020] [Indexed: 01/10/2023]
Abstract
INTRODUCTION The PACIFIC trial demonstrated that durvalumab significantly improved progression-free and overall survival (PFS/OS), versus placebo, in patients with Stage III NSCLC and stable or responding disease following concurrent, platinum-based chemoradiotherapy (CRT). A range of CT and RT regimens were permitted, and used, in the trial. We report post-hoc, exploratory analyses of clinical outcomes from PACIFIC according to CRT-related variables. METHODS Patients were randomized 2:1 (1-42 days post-CRT) to up to 12 months durvalumab (10 mg/kg intravenously every 2 weeks) or placebo. Efficacy and safety were analyzed in patient subgroups defined by the following baseline variables: platinum-based CT (cisplatin/carboplatin); vinorelbine, etoposide, or taxane-based CT (all yes/no); total RT dose (<60 Gy/60-66 Gy/>66 Gy); time from last RT dose to randomization (<14 days/≥14 days); and use of pre-CRT induction CT (yes/no). Treatment effects for time-to-event endpoints were estimated by hazard ratios (HRs) from unstratified Cox-proportional-hazards models. RESULTS Overall, 713 patients were randomized, of whom 709 received treatment in either the durvalumab (n/N = 473/476) or placebo arms (n/N = 236/237). Durvalumab improved PFS, versus placebo, across all subgroups (median follow up, 14.5 months; HR range, 0.34-0.63). Durvalumab improved OS across most subgroups (median follow up, 25.2 months; HR range, 0.35-0.86); however, the 95 % confidence interval (CI) of the estimated treatment effect crossed one for the subgroups of patients who received induction CT (HR, 0.78 [95 % CI, 0.51-1.20]); carboplatin (0.86 [0.60-1.23]); vinorelbine (0.79 [0.49-1.27]); and taxane-based CT (0.73 [0.51-1.04]); and patients who were randomized ≥14 days post-RT (0.81 [0.62-1.06]). Safety was broadly similar across the CRT subgroups. CONCLUSION Durvalumab prolonged PFS and OS irrespective of treatment variables related to prior CRT to which patients with Stage III NSCLC had previously stabilized or responded. Limited patient numbers and imbalances in baseline factors in each subgroup preclude robust conclusions.
Collapse
Affiliation(s)
- Corinne Faivre-Finn
- The University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK.
| | - David R Spigel
- Tennessee Oncology, Chattanooga, TN, USA; Sarah Cannon Research Institute, Nashville, TN, USA
| | - Suresh Senan
- Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands
| | - Corey Langer
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
| | - Bradford A Perez
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - Mustafa Özgüroğlu
- Istanbul University - Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey
| | - Davey Daniel
- Tennessee Oncology, Chattanooga, TN, USA; Sarah Cannon Research Institute, Nashville, TN, USA
| | | | - David Vicente
- Hospital Universitario Virgen Macarena, Seville, Spain
| | - Rina Hui
- Westmead Hospital and the University of Sydney, Sydney, NSW, Australia
| | | | - Luis Paz-Ares
- Hospital Universitario 12 de Octubre, Lung Cancer Unit CNIO-H12o, CiberOnc and Universidad Complutense, Madrid, Spain
| | | | | | | | - Scott J Antonia
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| |
Collapse
|
21
|
Abstract
Dysphagia and xerostomia are still among the most important acute and late side effects of radiotherapy. Technical developments over the past two decades have led to improved diagnostics and recognition as well as understanding of the causes of these side effects. Based on these findings and advances in both treatment planning and irradiation techniques, the incidence and severity of treatment-associated radiogenic late sequelae could be clearly reduced by the use of intensity-modulated radiotherapy (IMRT), which could contribute to marked long-term improvements in the quality of life in patients with head and neck cancer. Highly conformal techniques, such as proton therapy have the potential to further reduce treatment-associated side effects in head and neck oncology and are currently being prospectively tested within clinical trial protocols at several centers.
Collapse
Affiliation(s)
- A D Jensen
- Klinik für Strahlentherapie, Universitätsklinikum Gießen und Marburg, Klinikstr. 33, 35392, Gießen, Deutschland. .,FB 20 (Medizin), Philipps-Universität Marburg, Marburg, Deutschland.
| | - C Langer
- Klinik für HNO-Heilkunde, Kopf‑/Halschirurgie, Plastische Operationen, Universitätsklinikum Gießen und Marburg, Standort Gießen, Gießen, Deutschland.,Justus-Liebig Universität Gießen, Gießen, Deutschland
| |
Collapse
|
22
|
Barsky A, Maxwell R, Marmarelis M, Singhal S, Li Y, Alley E, Haas A, Busch T, Langer C, Simone C, Cengel K. Prospective Assessment of Proton Therapy for Malignant Pleural Mesothelioma. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
23
|
Kegelman T, Chao H, Simone C, Aggarwal C, Bauml J, Singh A, Levin W, Cengel K, Feigenberg S, Rengan R, Langer C, Ciunci C, Plastaras J, Berman A. Long-term Update of Outcomes of Proton Beam Re-irradiation for Locoregionally Recurrent Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
24
|
Berman A, Chao HH, Simone C, Kegelman T, Aggarwal C, Bauml J, Singh A, Levin W, Cengel K, Feigenberg S, Rengan R, Langer C, Ciunci C, Plastaras J. Long-term Outcomes of Proton Beam Re-irradiation for Locoregionally Recurrent Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.02.495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
25
|
Borghaei H, Langer C, Paz-Ares L, Rodriguez-Abreu D, Papadimitrakopoulou V, Garassino M, Houghton B, Kurata T, Cheng Y, Lin J, Pietanza C, Piperdi B, Gadgeel S. OA01.01 Pembrolizumab Plus Chemotherapy for Advanced NSCLC without Tumor PD-L1 Expression: Pooled Analysis of KN021G, KN189 and KN407. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
26
|
Grewal AS, Min EJ, Long Q, Grewal SK, Jain V, Levin WP, Cengel KA, Swisher-McClure S, Aggarwal C, Bauml JM, Singh A, Ciunci C, Cohen RB, Langer C, Feigenberg SJ, Berman AT. Early Tumor and Nodal Response in Patients with Locally Advanced Non-Small Cell Lung Carcinoma Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy. Int J Radiat Oncol Biol Phys 2019; 106:358-368. [PMID: 31654783 DOI: 10.1016/j.ijrobp.2019.10.019] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2019] [Revised: 09/04/2019] [Accepted: 10/10/2019] [Indexed: 12/28/2022]
Abstract
PURPOSE There are no established imaging biomarkers that predict response during chemoradiation for patients with locally advanced non-small cell lung carcinoma. At our institution, proton therapy (PT) patients undergo repeat computed tomography (CT) simulations twice during radiation. We hypothesized that tumor regression measured on these scans would separate early and late responders and that early response would translate into better outcomes. METHODS AND MATERIALS Patients underwent CT simulations before starting PT (CT0) and between weeks 1 to 3 (CT1) and weeks 4 to 7 (CT2) of PT. Primary tumor volume (TVR) and nodal volume (NVR) reduction were calculated at CT1 and CT2. Based on recursive partitioning analysis, early response at CT1 and CT2 was defined as ≥20% and ≥40%, respectively. Locoregional and overall progression-free survival (PFS), distant metastasis-free survival, and overall survival by response status were measured using Kaplan-Meier analysis. RESULTS Ninety-seven patients with locally advanced non-small cell lung carcinoma underwent definitive PT to a median dose of 66.6 Gy with concurrent chemotherapy. Median TVR and NVR at CT1 were 19% (0-79%) and 19% (0-75%), respectively. At CT2, they were 33% (2-98%) and 35% (0-89%), respectively. With a median follow-up of 25 months, the median overall survival and PFS for the entire cohort was 24.9 and 13.2 months, respectively. Compared with patients with TVR and NVR <20% at T1 and <40% at T2, patients with TVR and NVR ≥20% at CT1 and ≥40% at CT2 had improved median locoregional PFS (27.15 vs 12.97 months for TVR ≥40% vs <40%, P < .01, and 25.67 vs 12.09 months for NVR ≥40% vs <40%, P < .01) and median PFS (22.7 vs 9.2 months, P < .01, and 20.3 vs 7.9 months, P < .01), confirmed on multivariate Cox regression analysis. CONCLUSIONS Significantly improved outcomes in patients with early responses to therapy, as measured by TVR and NVR, were seen. Further study is warranted to determine whether treatment intensification will improve outcomes in slow-responding patients.
Collapse
Affiliation(s)
- Amardeep S Grewal
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Eun Jeong Min
- Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Qi Long
- Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Sharonjit K Grewal
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Varsha Jain
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - William P Levin
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Keith A Cengel
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Samuel Swisher-McClure
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Charu Aggarwal
- Medical Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Joshua M Bauml
- Medical Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Aditi Singh
- Medical Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Christine Ciunci
- Medical Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Roger B Cohen
- Medical Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Corey Langer
- Medical Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Steven J Feigenberg
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Abigail T Berman
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania.
| |
Collapse
|
27
|
Breslin S, Thompson J, Morrissette J, Ciunci C, Singh A, Aggarwal C, Cohen R, Langer C, Bauml J, Marmarelis M. P2.14-26 Outcomes in Patients with Compound Epidermal Growth Factor Receptor (EGFR) Mutations After Treatment with Tyrosine Kinase Inhibitors (TKIs). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
28
|
Aggarwal C, Thompson J, Chien A, Quinn K, Lefterova M, Nagy R, Yee S, Lariviere M, Ciunci C, Singh A, Bauml J, Cohen R, Langer C, Carpenter E. MA25.04 Blood-Based Tumor Mutation Burden as a Predictive Biomarker for Outcomes After Pembrolizumab Based First Line Therapy in Metastatic NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
29
|
Bauml J, Yoon D, Yan P, Katz S, Jeffries S, Davis C, Aggarwal C, Cohen R, Marmarelis M, Singh A, Ciunci C, Wherry E, Albelda S, Langer C, Huang A. P2.04-02 Effect of Chemotherapy, Chemoimmunotherapy, and Immunotherapy on Parameters of T Cell Exhaustion in Metastatic Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
30
|
Kier M, Marmarelis M, Davis C, Jain V, Berman A, Bauml J, Singh A, Ciunci C, Aggarwal C, Langer C, Cohen R. P1.01-63 Impact of Prior Radiation Pneumonitis on Incidence of Immunotherapy Related Pneumonitis. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
31
|
Grewal A, Min E, Long Q, Jain V, Levin W, Cengel K, Swisher-McClure S, Aggarwal C, Bauml J, Singh A, Ciunci C, Cohen R, Langer C, Feigenberg S, Berman A. Early Tumor and Nodal Response in Patients with Locally-advanced NSCLC Predicts for Oncologic Outcomes in Patients Treated with Concurrent Chemotherapy and Proton Therapy. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
32
|
Boyle MJ, Chan JA, Handayuni I, Reiling L, Feng G, Hilton A, Kurtovic L, Oyong D, Piera KA, Barber BE, William T, Eisen DP, Minigo G, Langer C, Drew DR, de Labastida Rivera F, Amante FH, Williams TN, Kinyanjui S, Marsh K, Doolan DL, Engwerda C, Fowkes FJI, Grigg MJ, Mueller I, McCarthy JS, Anstey NM, Beeson JG. IgM in human immunity to Plasmodium falciparum malaria. Sci Adv 2019; 5:eaax4489. [PMID: 31579826 PMCID: PMC6760923 DOI: 10.1126/sciadv.aax4489] [Citation(s) in RCA: 70] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/25/2019] [Accepted: 09/03/2019] [Indexed: 05/15/2023]
Abstract
Most studies on human immunity to malaria have focused on the roles of immunoglobulin G (IgG), whereas the roles of IgM remain undefined. Analyzing multiple human cohorts to assess the dynamics of malaria-specific IgM during experimentally induced and naturally acquired malaria, we identified IgM activity against blood-stage parasites. We found that merozoite-specific IgM appears rapidly in Plasmodium falciparum infection and is prominent during malaria in children and adults with lifetime exposure, together with IgG. Unexpectedly, IgM persisted for extended periods of time; we found no difference in decay of merozoite-specific IgM over time compared to that of IgG. IgM blocked merozoite invasion of red blood cells in a complement-dependent manner. IgM was also associated with significantly reduced risk of clinical malaria in a longitudinal cohort of children. These findings suggest that merozoite-specific IgM is an important functional and long-lived antibody response targeting blood-stage malaria parasites that contributes to malaria immunity.
Collapse
Affiliation(s)
- M. J. Boyle
- Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia
- Global and Tropical Health Division, Menzies School of Health Research, Darwin, Northern Territory, Australia
- QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
- Corresponding author. (M.J.B.); (J.G.B.)
| | - J. A. Chan
- Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia
| | - I. Handayuni
- Global and Tropical Health Division, Menzies School of Health Research, Darwin, Northern Territory, Australia
| | - L. Reiling
- Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia
| | - G. Feng
- Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia
- Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
| | - A. Hilton
- Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia
| | - L. Kurtovic
- Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia
- Department of Immunology and Pathology, Monash University, Melbourne, Victoria, Australia
| | - D. Oyong
- Global and Tropical Health Division, Menzies School of Health Research, Darwin, Northern Territory, Australia
- Charles Darwin University, Darwin, Northern Territory, Australia
| | - K. A. Piera
- Global and Tropical Health Division, Menzies School of Health Research, Darwin, Northern Territory, Australia
| | - B. E. Barber
- Global and Tropical Health Division, Menzies School of Health Research, Darwin, Northern Territory, Australia
- QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
- Infectious Diseases Society Sabah-Menzies School of Health Research Clinical Research Unit, Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia
| | - T. William
- Infectious Diseases Society Sabah-Menzies School of Health Research Clinical Research Unit, Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia
- Gleneagles Hospital Kota Kinabalu Sabah, Malaysia
| | - D. P. Eisen
- Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Queensland, Australia
| | - G. Minigo
- Global and Tropical Health Division, Menzies School of Health Research, Darwin, Northern Territory, Australia
- Charles Darwin University, Darwin, Northern Territory, Australia
| | - C. Langer
- Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia
| | - D. R. Drew
- Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia
| | | | - F. H. Amante
- QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - T. N. Williams
- Kenya Medical Research Institute (KEMRI), Centre for Geographic Medicine, Coast, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Imperial College, London, UK
| | - S. Kinyanjui
- Kenya Medical Research Institute (KEMRI), Centre for Geographic Medicine, Coast, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - K. Marsh
- Kenya Medical Research Institute (KEMRI), Centre for Geographic Medicine, Coast, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - D. L. Doolan
- Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Queensland, Australia
| | - C. Engwerda
- QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - F. J. I. Fowkes
- Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia
- Department of Epidemiology and Preventive Medicine, Department of Infectious Diseases, Monash University, Melbourne, Victoria, Australia
| | - M. J. Grigg
- Global and Tropical Health Division, Menzies School of Health Research, Darwin, Northern Territory, Australia
- Infectious Diseases Society Sabah-Menzies School of Health Research Clinical Research Unit, Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia
| | - I. Mueller
- Walter and Eliza Hall Institute, Melbourne, Victoria, Australia
- Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia
- Department of Parasites and Insect Vectors, Institute Pasteur, Paris, France
| | - J. S. McCarthy
- QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
- The University of Queensland, Brisbane, Queensland, Australia
| | - N. M. Anstey
- Global and Tropical Health Division, Menzies School of Health Research, Darwin, Northern Territory, Australia
- Charles Darwin University, Darwin, Northern Territory, Australia
| | - J. G. Beeson
- Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia
- Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
- Department of Microbiology and Central Clinical School, Monash University, Melbourne, Victoria, Australia
- Corresponding author. (M.J.B.); (J.G.B.)
| |
Collapse
|
33
|
Wolf C, Langer C, Montes F, Pereira J, Ong WJ, Poxon-Pearson T, Ahn S, Ayoub S, Baumann T, Bazin D, Bender PC, Brown BA, Browne J, Crawford H, Cyburt RH, Deleeuw E, Elman B, Fiebiger S, Gade A, Gastis P, Lipschutz S, Longfellow B, Meisel Z, Nunes FM, Perdikakis G, Reifarth R, Richter WA, Schatz H, Schmidt K, Schmitt J, Sullivan C, Titus R, Weisshaar D, Woods PJ, Zamora JC, Zegers RGT. Constraining the Neutron Star Compactness: Extraction of the ^{23}Al(p,γ) Reaction Rate for the rp Process. Phys Rev Lett 2019; 122:232701. [PMID: 31298878 DOI: 10.1103/physrevlett.122.232701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/28/2019] [Revised: 04/10/2019] [Indexed: 06/10/2023]
Abstract
The ^{23}Al(p,γ)^{24}Si reaction is among the most important reactions driving the energy generation in type-I x-ray bursts. However, the present reaction-rate uncertainty limits constraints on neutron star properties that can be achieved with burst model-observation comparisons. Here, we present a novel technique for constraining this important reaction by combining the GRETINA array with the neutron detector LENDA coupled to the S800 spectrograph at the National Superconducting Cyclotron Laboratory. The ^{23}Al(d,n) reaction was used to populate the astrophysically important states in ^{24}Si. This enables a measurement in complete kinematics for extracting all relevant inputs necessary to calculate the reaction rate. For the first time, a predicted close-lying doublet of a 2_{2}^{+} and (4_{1}^{+},0_{2}^{+}) state in ^{24}Si was disentangled, finally resolving conflicting results from two previous measurements. Moreover, it was possible to extract spectroscopic factors using GRETINA and LENDA simultaneously. This new technique may be used to constrain other important reaction rates for various astrophysical scenarios.
Collapse
Affiliation(s)
- C Wolf
- Institute for Applied Physics, Goethe University, 60438 Frankfurt am Main, Germany
| | - C Langer
- Institute for Applied Physics, Goethe University, 60438 Frankfurt am Main, Germany
| | - F Montes
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- JINA Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
| | - J Pereira
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- JINA Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
| | - W-J Ong
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- JINA Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - T Poxon-Pearson
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - S Ahn
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- JINA Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
| | - S Ayoub
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - T Baumann
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - D Bazin
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - P C Bender
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - B A Brown
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - J Browne
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - H Crawford
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - R H Cyburt
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- JINA Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
| | - E Deleeuw
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - B Elman
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - S Fiebiger
- Institute for Applied Physics, Goethe University, 60438 Frankfurt am Main, Germany
| | - A Gade
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- JINA Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - P Gastis
- JINA Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Central Michigan University, Mount Pleasant, Michigan 48859, USA
| | - S Lipschutz
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - B Longfellow
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - Z Meisel
- JINA Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Institute of Nuclear & Particle Physics, Department of Physics & Astronomy, Ohio University, Athens, Ohio 45701, USA
| | - F M Nunes
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - G Perdikakis
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- JINA Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Central Michigan University, Mount Pleasant, Michigan 48859, USA
| | - R Reifarth
- Institute for Applied Physics, Goethe University, 60438 Frankfurt am Main, Germany
| | - W A Richter
- Department of Physics, University of Stellenbosch, Matieland 7602, South Africa
- iThemba LABS, P.O. Box 722, Somerset West 7129, South Africa
| | - H Schatz
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- JINA Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - K Schmidt
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- JINA Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
| | - J Schmitt
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- JINA Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
| | - C Sullivan
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- JINA Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - R Titus
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - D Weisshaar
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - P J Woods
- University of Edinburgh, Edinburgh EH9 3JZ, United Kingdom
| | - J C Zamora
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- JINA Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - R G T Zegers
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- JINA Center for the Evolution of the Elements, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| |
Collapse
|
34
|
Feuchtner GM, Barbieri F, Langer C, Beyer C, Friedrich G, Plank F. 38The secret of INOCA: High-risk plaque but not calcium density predicts ischemia, and their relationship with perivascular fat gradient. Eur Heart J Cardiovasc Imaging 2019. [DOI: 10.1093/ehjci/jez135.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | - F Barbieri
- Innsbruck Medical University, Innsbruck, Austria
| | - C Langer
- Innsbruck Medical University, Innsbruck, Austria
| | - C Beyer
- Innsbruck Medical University, Innsbruck, Austria
| | - G Friedrich
- Innsbruck Medical University, Innsbruck, Austria
| | - F Plank
- Innsbruck Medical University, Innsbruck, Austria
| |
Collapse
|
35
|
Glorius J, Langer C, Slavkovská Z, Bott L, Brandau C, Brückner B, Blaum K, Chen X, Dababneh S, Davinson T, Erbacher P, Fiebiger S, Gaßner T, Göbel K, Groothuis M, Gumberidze A, Gyürky G, Heil M, Hess R, Hensch R, Hillmann P, Hillenbrand PM, Hinrichs O, Jurado B, Kausch T, Khodaparast A, Kisselbach T, Klapper N, Kozhuharov C, Kurtulgil D, Lane G, Lederer-Woods C, Lestinsky M, Litvinov S, Litvinov YA, Löher B, Nolden F, Petridis N, Popp U, Rauscher T, Reed M, Reifarth R, Sanjari MS, Savran D, Simon H, Spillmann U, Steck M, Stöhlker T, Stumm J, Surzhykov A, Szücs T, Nguyen TT, Taremi Zadeh A, Thomas B, Torilov SY, Törnqvist H, Träger M, Trageser C, Trotsenko S, Varga L, Volknandt M, Weick H, Weigand M, Wolf C, Woods PJ, Xing YM. Approaching the Gamow Window with Stored Ions: Direct Measurement of ^{124}Xe(p,γ) in the ESR Storage Ring. Phys Rev Lett 2019; 122:092701. [PMID: 30932526 DOI: 10.1103/physrevlett.122.092701] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/06/2018] [Revised: 01/31/2019] [Indexed: 06/09/2023]
Abstract
We report the first measurement of low-energy proton-capture cross sections of ^{124}Xe in a heavy-ion storage ring. ^{124}Xe^{54+} ions of five different beam energies between 5.5 and 8 AMeV were stored to collide with a windowless hydrogen target. The ^{125}Cs reaction products were directly detected. The interaction energies are located on the high energy tail of the Gamow window for hot, explosive scenarios such as supernovae and x-ray binaries. The results serve as an important test of predicted astrophysical reaction rates in this mass range. Good agreement in the prediction of the astrophysically important proton width at low energy is found, with only a 30% difference between measurement and theory. Larger deviations are found above the neutron emission threshold, where also neutron and γ widths significantly impact the cross sections. The newly established experimental method is a very powerful tool to investigate nuclear reactions on rare ion beams at low center-of-mass energies.
Collapse
Affiliation(s)
- J Glorius
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - C Langer
- Goethe Universität, Frankfurt am Main, Germany
| | | | - L Bott
- Goethe Universität, Frankfurt am Main, Germany
| | - C Brandau
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
- Justus-Liebig Universität, Gießen, Germany
| | - B Brückner
- Goethe Universität, Frankfurt am Main, Germany
| | - K Blaum
- Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany
| | - X Chen
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China
| | - S Dababneh
- Al-Balqa Applied University, Salt, Jordan
| | - T Davinson
- University of Edinburgh, Edinburgh, United Kingdom
| | - P Erbacher
- Goethe Universität, Frankfurt am Main, Germany
| | - S Fiebiger
- Goethe Universität, Frankfurt am Main, Germany
| | - T Gaßner
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - K Göbel
- Goethe Universität, Frankfurt am Main, Germany
| | - M Groothuis
- Goethe Universität, Frankfurt am Main, Germany
| | - A Gumberidze
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - G Gyürky
- Institute for Nuclear Research (MTA Atomki), Debrecen, Hungary
| | - M Heil
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - R Hess
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - R Hensch
- Goethe Universität, Frankfurt am Main, Germany
| | - P Hillmann
- Goethe Universität, Frankfurt am Main, Germany
| | - P-M Hillenbrand
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - O Hinrichs
- Goethe Universität, Frankfurt am Main, Germany
| | - B Jurado
- CENBG, CNRS-IN2P3, Gradignan, France
| | - T Kausch
- Goethe Universität, Frankfurt am Main, Germany
| | - A Khodaparast
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
- Goethe Universität, Frankfurt am Main, Germany
| | | | - N Klapper
- Goethe Universität, Frankfurt am Main, Germany
| | - C Kozhuharov
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - D Kurtulgil
- Goethe Universität, Frankfurt am Main, Germany
| | - G Lane
- Australian National University, Canberra, Australia
| | | | - M Lestinsky
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - S Litvinov
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - Yu A Litvinov
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - B Löher
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
- Technische Universität Darmstadt, Darmstadt, Germany
| | - F Nolden
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - N Petridis
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - U Popp
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - T Rauscher
- Department of Physics, University of Basel, Switzerland
- Centre for Astrophysics Research, University of Hertfordshire, Hatfield, United Kingdom
| | - M Reed
- Australian National University, Canberra, Australia
| | - R Reifarth
- Goethe Universität, Frankfurt am Main, Germany
| | - M S Sanjari
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - D Savran
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - H Simon
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - U Spillmann
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - M Steck
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - T Stöhlker
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
- Helmholtz-Insitut Jena, Jena, Germany
| | - J Stumm
- Goethe Universität, Frankfurt am Main, Germany
| | - A Surzhykov
- Physikalisch-Technische Bundesanstalt, Braunschweig, Germany
- Technische Universität Braunschweig, Braunschweig, Germany
| | - T Szücs
- Institute for Nuclear Research (MTA Atomki), Debrecen, Hungary
| | - T T Nguyen
- Goethe Universität, Frankfurt am Main, Germany
| | | | - B Thomas
- Goethe Universität, Frankfurt am Main, Germany
| | - S Yu Torilov
- St. Petersburg State University, St. Petersburg, Russia
| | - H Törnqvist
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
- Technische Universität Darmstadt, Darmstadt, Germany
| | - M Träger
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - C Trageser
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
- Justus-Liebig Universität, Gießen, Germany
| | - S Trotsenko
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - L Varga
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - M Volknandt
- Goethe Universität, Frankfurt am Main, Germany
| | - H Weick
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
| | - M Weigand
- Goethe Universität, Frankfurt am Main, Germany
| | - C Wolf
- Goethe Universität, Frankfurt am Main, Germany
| | - P J Woods
- University of Edinburgh, Edinburgh, United Kingdom
| | - Y M Xing
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China
| |
Collapse
|
36
|
Schnoll R, Leone F, Veluz-Wilkins A, Miele A, Hole A, Jao NC, Paul Wileyto E, Carroll AJ, Kalhan R, Patel J, Langer C, Lubitz SF, Hitsman B. A randomized controlled trial of 24 weeks of varenicline for tobacco use among cancer patients: Efficacy, safety, and adherence. Psychooncology 2019; 28:561-569. [PMID: 30680852 DOI: 10.1002/pon.4978] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2018] [Revised: 12/23/2018] [Accepted: 12/31/2018] [Indexed: 12/13/2022]
Abstract
OBJECTIVE Continuing to smoke after a cancer diagnosis undermines prognosis. Yet few trials have tested Food and Drug Administration (FDA)-approved tobacco use medications in this population. Extended use varenicline may represent an effective treatment for cancer patients who smoke given barriers to cessation including a prolonged time line for relapse. METHODS A placebo-controlled randomized trial tested 12 weeks of varenicline plus 12 weeks of placebo (standard [ST]) vs 24 weeks of varenicline (extended [ET]) with seven counseling sessions for treatment-seeking cancer patients who smoke (N = 207). Primary outcomes were 7-day biochemically confirmed abstinence at weeks 24 and 52. Treatment adherence and side effects, adverse and serious adverse events, and blood pressure were assessed. RESULTS Point prevalence and continuous abstinence quit rates at weeks 24 and 52 were not significantly different across treatment arms (P's > 0.05). Adherence (43% of sample) significantly interacted with treatment arm for week 24 point prevalence (odds ratio [OR] = 2.31; 95% confidence interval [CI], 1.15-4.63; P = 0.02) and continuous (OR = 5.82; 95% CI, 2.66-12.71; P < 0.001) abstinence. For both outcomes, adherent participants who received ET reported higher abstinence (60.5% and 44.2%) vs ST (44.7% and 27.7%), but differences in quit rates between arms were not significant for nonadherent participants (ET: 9.7% and 4.8%; ST: 12.7% and 10.9%). There were no significant differences between treatment arms on side effects, adverse and serious adverse events, and rates of high blood pressure (P's > 0.05). CONCLUSIONS Compared with ST, ET varenicline does not increase patient risk and increases smoking cessation rates among patients who adhere to treatment. Studies are needed to identify effective methods to increase medication adherence to treat patient tobacco use effectively.
Collapse
Affiliation(s)
- Robert Schnoll
- Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Frank Leone
- Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Anna Veluz-Wilkins
- Department of Preventive Medicine, Northwestern University, Chicago, Illinois
| | - Andrew Miele
- Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Anita Hole
- Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Nancy C Jao
- Department of Preventive Medicine, Northwestern University, Chicago, Illinois
| | - E Paul Wileyto
- Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Allison J Carroll
- Department of Preventive Medicine, Northwestern University, Chicago, Illinois
| | - Ravi Kalhan
- Department of Preventive Medicine, Northwestern University, Chicago, Illinois.,Department of Medicine, Northwestern University, Chicago, Illinois
| | - Jyoti Patel
- Department of Medicine, University of Chicago, Chicago, Illinois
| | - Corey Langer
- Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Su Fen Lubitz
- Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Brian Hitsman
- Department of Preventive Medicine, Feinberg School of Medicine, and Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois
| |
Collapse
|
37
|
Kim D, Huber R, Ahn M, Langer C, Tiseo M, West H, Groen H, Reckamp K, Hochmair M, Leighl N, Hansen K, Gettinger S, Paz-Ares Rodriguez L, Kim E, Smit E, Kim S, Reichmann W, Kerstein D, Camidge D. Brigatinib in crizotinib-refractory ALK+ non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial. Lung Cancer 2019. [DOI: 10.1016/s0169-5002(19)30120-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
38
|
Gridelli C, de Castro Carpeno J, Dingemans AMC, Griesinger F, Grossi F, Langer C, Ohe Y, Syrigos K, Thatcher N, Das-Gupta A, Truman M, Donica M, Smoljanovic V, Bennouna J. Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial. JAMA Oncol 2018; 4:e183486. [PMID: 30177994 DOI: 10.1001/jamaoncol.2018.3486] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Importance Bevacizumab treatment beyond progression has been investigated in breast and metastatic colorectal cancers. Avastin in All Lines Lung (AvaALL) is the first randomized phase 3 study of bevacizumab across multiple lines of treatment beyond progression in non-small cell lung cancer (NSCLC). Objective To assess the efficacy and safety of continuous bevacizumab treatment beyond first progression in NSCLC. Design, Setting, and Participants AvaALL was a randomized, open-label, phase 3b trial, conducted from 2011 to 2015 in 123 centers worldwide. Patients with nonsquamous NSCLC previously treated with first-line bevacizumab plus platinum-doublet chemotherapy and at least 2 cycles of bevacizumab maintenance were randomized (1:1) at first progression to receive bevacizumab plus standard of care (SOC) or SOC alone. Interventions Patients received bevacizumab (7.5 or 15 mg/kg intravenously every 21 days) and/or investigator's choice of SOC. For subsequent lines, patients treated with bevacizumab received SOC with or without bevacizumab; the SOC arm received SOC only. Main Outcomes and Measures The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival from first to second (PFS2) and third progression (PFS3), time to second (TTP2) and third progression (TTP3), and safety. Results Between June 2011 and January 2015, 485 patients (median age, 63.0 years [range, 26-84 years]; 293 [60.4%] male) were randomized. Median OS was not significantly longer with bevacizumab plus SOC vs SOC alone: 11.9 (90% CI, 10.2-13.7) vs 10.2 (90% CI, 8.6-11.9) months (hazard ratio [HR], 0.84; 90% CI, 0.71-1.00; P = .104). Median PFS2 was numerically longer with bevacizumab plus SOC vs SOC alone: 5.5 (90% CI, 4.2-5.7) vs 4.0 (90% CI, 3.4-4.3) months (HR, 0.83; 90% CI, 0.70-0.98; P = .06). Median PFS3 appeared longer with bevacizumab plus SOC vs SOC alone: 4.0 (90% CI, 2.9-4.5) vs 2.6 (90% CI, 2.3-2.9) months (HR, 0.63; 90% CI, 0.49-0.83), as did TTP2 and TTP3. Grade 3/4 adverse events were more frequent with bevacizumab plus SOC (186 [76.5%]) vs SOC alone (140 [60.3%]). No new safety signals were observed. Conclusions and Relevance The primary end point was not met; however, OS was underpowered according to initial statistical assumptions. Continued therapy beyond first progression led to improved PFS3 (but not PFS2), TTP2, and TTP3. Although a result with P = .06 for PFS2 would conventionally be considered significant at a specified 2-sided α of .10, in the absence of adjustments for multiplicity, this result could be a chance finding. No new safety signals were identified with bevacizumab treatment beyond progression. Trial Registration clinicaltrialsregister.eu Identifier: 2010-022645-14; ClinicalTrials.gov identifier: NCT01351415.
Collapse
Affiliation(s)
- Cesare Gridelli
- Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy
| | | | - Anne-Marie C Dingemans
- Department of Pulmonology, Maastricht University Medical Center, Maastricht, the Netherlands
| | - Frank Griesinger
- Department of Hematology and Oncology, University Department of Internal Medicine-Oncology, Pius-Hospital, University of Oldenburg, Oldenburg, Germany
| | - Francesco Grossi
- Lung Cancer Unit, Ospedale Policlinico San Martino, Genova, Italy
| | - Corey Langer
- Thoracic Oncology Unit, Abramson Cancer Center, University of Pennsylvania, Philadelphia
| | - Yuichiro Ohe
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | | | - Nick Thatcher
- Christie Hospital NHS Trust, Manchester, United Kingdom
| | | | - Matt Truman
- Roche Products Pty Ltd, Sydney, New South Wales, Australia.,Now with OzBiostat Pty Ltd, Manly, New South Wales, Australia
| | | | | | | |
Collapse
|
39
|
Rengan R, Mick R, Pryma D, Lin L, Plastaras J, Simone C, Gupta A, Evans T, Stevenson J, Langer C, Kucharczuk J, Friedberg J, Lam S, Patsch D, Hahn S, Maity A. Long-term Results of a Phase I/II Trial of Nelfinavir with Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.06.135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
40
|
Marmarelis M, Bange E, Bagley S, Hwang W, Yang Y, Thompson J, Bauml J, Ciunci C, Alley E, Morrissette J, Cohen R, Langer C, Carpenter E, Aggarwal C. P1.01-64 Impact of STK11 Co-Mutation on Outcomes Following Immunotherapy Among Patients with TP53 and KRAS Mutated Stage IV NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.620] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
41
|
Bauml J, Mick R, Ciunci C, Aggarwal C, Davis C, Evans T, Deshpande C, Miller L, Patel P, Alley E, Knepley C, Mutale F, Cohen R, Langer C. OA07.01 Phase II Study of Pembrolizumab for Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Following Completion of Locally Ablative Therapy (LAT). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.269] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
42
|
Gutierrez M, Wozniak A, Langer C, Fang B, Suero-Abreu G, Norden A, Bedell K, Schaffer J, Collins A, Schultz E, Stone B, Narayanan V, Goldberg S. P2.01-42 Impact of Tobacco Smoking on Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer in the Era of Targeted Therapy. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1096] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Seider MJ, Pugh SL, Langer C, Wyatt G, Demas W, Rashtian A, Clausen CL, Derdel JD, Cleary SF, Peters CA, Ramalingam A, Clarkson JE, Tomblyn M, Rabinovitch RA, Kachnic LA, Berk LB. Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial. Ann Nucl Med 2018; 32:553-560. [PMID: 30094545 DOI: 10.1007/s12149-018-1278-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Accepted: 07/11/2018] [Indexed: 01/01/2023]
Abstract
BACKGROUND Skeletal-related events (SREs), common sequelae of metastatic cancer, are reduced by bisphosphonates. In this study, it was postulated that radiopharmaceuticals, added to bisphosphonates, could further decrease the incidence of SREs. METHODS NRG Oncology RTOG 0517 randomized patients with breast, lung, and prostate cancer and blastic bone metastases to either zoledronic acid (ZA) alone or ZA plus radiopharmaceuticals (Sr-89 or Sm-153). The primary endpoint was time to development of SREs. Secondary objectives included quality of life (QOL), pain control, overall survival (OS), and toxicity. RESULTS 261 patients (median age 68; 62% male; 55% prostate, 35% breast, 10% lung) were accrued between July 2006 and February 2011. The study closed early due to a lower than expected rate of SREs. 52 (42%) patients in the ZA arm and 49 (40%) in the radiopharmaceutical arm experienced an SRE. Median time free of SREs was 29.9 and 27.4 months, respectively (p = 0.84). Median OS in the ZA arm and radiopharmaceutical arms was 32.1 and 26.9 months, respectively (p = 0.37). Cox proportional hazards regression model showed that primary disease site (lung) and number of bone metastases (> 2) had a negative impact on OS (p < 0.0001, p = 0.01, respectively). The addition of radiopharmaceuticals to ZA led to a significant reduction in pain at 1 month based on BPI worst score (p = 0.02). No other group differences were noted for QOL or toxicity. CONCLUSION The addition of radiopharmaceuticals to bisphosphonates did not alter time to SREs or OS for patients with breast, lung, prostate cancers and blastic bone metastases, although it was associated with significant pain reduction at 1 month. CLINICAL TRIAL REGISTRY This protocol (RTOG 0517) is registered with ClinicalTrials.gov (NCT00365105), and may be viewed online at http://www.clinicaltrials.gov/ct2/show/NCT00365105?term=RTOG+0517&rank=1 .
Collapse
Affiliation(s)
| | - Stephanie L Pugh
- NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA
| | - Corey Langer
- University of Pennsylvania, Philadelphia, PA, USA
| | - Gwen Wyatt
- Michigan State University, East Lansing, MI, USA
| | | | - Afshin Rashtian
- University of Southern California-Los Angeles, Los Angeles, CA, USA
| | | | - Jerome David Derdel
- Mount Nittany Medical Center Penn State Cancer Institute, State College, PA, USA
| | | | | | | | - James E Clarkson
- Singing River Hospital Regional Cancer Center, Pascagoula, MS, USA
| | - Michael Tomblyn
- University of South Florida Morsani School of Medicine, Tampa, FL, USA
| | | | - Lisa A Kachnic
- Boston Medical Center MBCCOP, Boston, MA, USA.,Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA
| | | | | |
Collapse
|
44
|
Wiemer M, Schäufele T, Schmitz T, Hoffmann S, Comberg T, Eggebrecht H, Langer C. Herzkatheter: Diagnostik und Intervention über die Arteria radialis. Kardiologe 2018. [DOI: 10.1007/s12181-018-0264-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
45
|
Hirsh V, Wan Y, Lin FJ, Margunato-Debay S, Ong TJ, Botteman M, Langer C. Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non-Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin. Clin Lung Cancer 2018; 19:401-409.e4. [PMID: 29903552 DOI: 10.1016/j.cllc.2018.04.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2017] [Revised: 03/16/2018] [Accepted: 04/24/2018] [Indexed: 10/17/2022]
Abstract
BACKGROUND First-line nab-paclitaxel/carboplatin was associated with a significantly improved overall response rate (primary endpoint) versus paclitaxel/carboplatin in a phase III trial of advanced non-small-cell lung cancer (NSCLC). We report the results of an analysis evaluating the correlation of response and the time to response with survival and quality-adjusted outcomes. PATIENTS AND METHODS Using a landmark approach, progression-free survival (PFS), overall survival (OS), and quality-adjusted time without symptoms or toxicity (Q-TWiST) were compared between patients with a confirmed partial or complete response at or before 6 weeks (≤ 6-week responders) and those without (≤ 6-week nonresponders). The outcomes were also analyzed in two 12-week landmark analyses: ≤ 12-week responders versus ≤ 12-week nonresponders and early responders (≤ 6 weeks) versus late responders (6-12 weeks) versus ≤ 12-week nonresponders. RESULTS The median OS and PFS for the ≤ 6-week responders versus ≤ 6-week nonresponders were 14.5 versus 10.3 months (P < .001) and 5.5 versus 4.5 months (P = .002), respectively. The ≤ 6-week responders gained 2.1 months of mean Q-TWiST. The median OS and PFS for the ≤ 12-week responders versus ≤ 12-week nonresponders were 16.3 versus 8.4 months and 5.3 versus 2.8 months (both P < .001), respectively, and the ≤ 12-week responders gained 3.2 months of mean Q-TWiST. The median OS was 13.1, 16.6, and 8.4 months (P < .001), the median PFS was 4.1, 6.7, and 2.8 months (P < .001), and the mean Q-TWiST was 10.2, 11.7, and 7.8 months for the early responders, late responders, and ≤ 12-week nonresponders, respectively. Both early and late responders had significantly longer Q-TWiST compared with the ≤ 12-week nonresponders (difference, +2.4 and +3.9 months, respectively; P < .05). CONCLUSION These results underscore response as an important surrogate for assessment of long-term treatment outcomes in advanced NSCLC.
Collapse
Affiliation(s)
- Vera Hirsh
- Department of Oncology, McGill University Health Centre, Cedars Cancer Centre, Montreal, QC, Canada.
| | - Yin Wan
- Pharmerit North America, Bethesda, MD
| | | | | | | | | | - Corey Langer
- Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
46
|
Revel A, Marqués FM, Sorlin O, Aumann T, Caesar C, Holl M, Panin V, Vandebrouck M, Wamers F, Alvarez-Pol H, Atar L, Avdeichikov V, Beceiro-Novo S, Bemmerer D, Benlliure J, Bertulani CA, Boillos JM, Boretzky K, Borge MJG, Caamaño M, Casarejos E, Catford WN, Cederkäll J, Chartier M, Chulkov L, Cortina-Gil D, Cravo E, Crespo R, Datta Pramanik U, Díaz Fernández P, Dillmann I, Elekes Z, Enders J, Ershova O, Estradé A, Farinon F, Fraile LM, Freer M, Galaviz D, Geissel H, Gernhäuser R, Golubev P, Göbel K, Hagdahl J, Heftrich T, Heil M, Heine M, Heinz A, Henriques A, Ignatov A, Johansson HT, Jonson B, Kahlbow J, Kalantar-Nayestanaki N, Kanungo R, Kelic-Heil A, Knyazev A, Kröll T, Kurz N, Labiche M, Langer C, Le Bleis T, Lemmon R, Lindberg S, Machado J, Marganiec J, Movsesyan A, Nacher E, Najafi M, Nilsson T, Nociforo C, Paschalis S, Perea A, Petri M, Pietri S, Plag R, Reifarth R, Ribeiro G, Rigollet C, Röder M, Rossi D, Savran D, Scheit H, Simon H, Syndikus I, Taylor JT, Tengblad O, Thies R, Togano Y, Velho P, Volkov V, Wagner A, Weick H, Wheldon C, Wilson G, Winfield JS, Woods P, Yakorev D, Zhukov M, Zilges A, Zuber K. Strong Neutron Pairing in core+4n Nuclei. Phys Rev Lett 2018; 120:152504. [PMID: 29756867 DOI: 10.1103/physrevlett.120.152504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/08/2018] [Revised: 02/17/2018] [Indexed: 06/08/2023]
Abstract
The emission of neutron pairs from the neutron-rich N=12 isotones ^{18}C and ^{20}O has been studied by high-energy nucleon knockout from ^{19}N and ^{21}O secondary beams, populating unbound states of the two isotones up to 15 MeV above their two-neutron emission thresholds. The analysis of triple fragment-n-n correlations shows that the decay ^{19}N(-1p)^{18}C^{*}→^{16}C+n+n is clearly dominated by direct pair emission. The two-neutron correlation strength, the largest ever observed, suggests the predominance of a ^{14}C core surrounded by four valence neutrons arranged in strongly correlated pairs. On the other hand, a significant competition of a sequential branch is found in the decay ^{21}O(-1n)^{20}O^{*}→^{18}O+n+n, attributed to its formation through the knockout of a deeply bound neutron that breaks the ^{16}O core and reduces the number of pairs.
Collapse
Affiliation(s)
- A Revel
- Grand Accélérateur National d'Ions Lourds (GANIL), CEA/DRF-CNRS/IN2P3, Bvd Henri Becquerel, 14076 Caen, France
- LPC Caen, ENSICAEN, Université de Caen, CNRS/IN2P3, F-14050 CAEN Cedex, France
| | - F M Marqués
- LPC Caen, ENSICAEN, Université de Caen, CNRS/IN2P3, F-14050 CAEN Cedex, France
| | - O Sorlin
- Grand Accélérateur National d'Ions Lourds (GANIL), CEA/DRF-CNRS/IN2P3, Bvd Henri Becquerel, 14076 Caen, France
| | - T Aumann
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - C Caesar
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - M Holl
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - V Panin
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - M Vandebrouck
- Irfu, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - F Wamers
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - H Alvarez-Pol
- IGFAE, Instituto Galego de Física de Altas Enerxías, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - L Atar
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - V Avdeichikov
- Department of Physics, Lund University, 22100 Lund, Sweden
| | - S Beceiro-Novo
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - D Bemmerer
- Helmholtz-Zentrum Dresden-Rossendorf, 01328, Dresden, Germany
| | - J Benlliure
- IGFAE, Instituto Galego de Física de Altas Enerxías, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - C A Bertulani
- Department of Physics and Astronomy, Texas A&M University-Commerce, Commerce, Texas 75429, USA
| | - J M Boillos
- IGFAE, Instituto Galego de Física de Altas Enerxías, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - K Boretzky
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - M J G Borge
- Instituto de Estructura de la Materia, CSIC, Serrano 113 bis, 28006 Madrid, Spain
| | - M Caamaño
- IGFAE, Instituto Galego de Física de Altas Enerxías, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | | | - W N Catford
- Department of Physics, University of Surrey, Guildford GU2 7XH, United Kingdom
| | - J Cederkäll
- Department of Physics, Lund University, 22100 Lund, Sweden
| | - M Chartier
- Oliver Lodge Laboratory, University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - L Chulkov
- NRC Kurchatov Institute, Ru-123182 Moscow, Russia
- ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - D Cortina-Gil
- IGFAE, Instituto Galego de Física de Altas Enerxías, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - E Cravo
- Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, Portugal
| | - R Crespo
- Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal
| | - U Datta Pramanik
- Saha Institute of Nuclear Physics, 1/AF Bidhan Nagar, Kolkata 700064, India
| | - P Díaz Fernández
- IGFAE, Instituto Galego de Física de Altas Enerxías, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - I Dillmann
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
- II. Physikalisches Institut, Universität Gieß en, 35392 Gießen, Germany
| | - Z Elekes
- MTA Atomki, 4001 Debrecen, Hungary
| | - J Enders
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - O Ershova
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - A Estradé
- School of Physics and Astronomy, University of Edinburgh, Edinburgh EH9 3JZ, United Kingdom
| | - F Farinon
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - L M Fraile
- Grupo de Física Nuclear y UPARCOS, Universidad Complutense de Madrid, CEI Moncloa, 28040 Madrid, Spain
| | - M Freer
- School of Physics and Astronomy, University of Birmingham, Birmingham B15 2TT, United Kingdom
| | - D Galaviz
- Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, Portugal
- Laboratório de Instrumentação e Física Experimental de Partículas-LIP, 1000-149 Lisbon, Portugal
| | - H Geissel
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - R Gernhäuser
- Physik Department E12, Technische Universität München, 85748 Garching, Germany
| | - P Golubev
- Department of Physics, Lund University, 22100 Lund, Sweden
| | - K Göbel
- Goethe-Universität Frankfurt am Main, 60438 Frankfurt am Main, Germany
| | - J Hagdahl
- Institutionen för Fysik, Chalmers Tekniska Högskola, 412 96 Göteborg, Sweden
| | - T Heftrich
- Goethe-Universität Frankfurt am Main, 60438 Frankfurt am Main, Germany
| | - M Heil
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - M Heine
- IPHC-CNRS/Université de Strasbourg, 67037 Strasbourg, France
| | - A Heinz
- Institutionen för Fysik, Chalmers Tekniska Högskola, 412 96 Göteborg, Sweden
| | - A Henriques
- Laboratório de Instrumentação e Física Experimental de Partículas-LIP, 1000-149 Lisbon, Portugal
| | - A Ignatov
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - H T Johansson
- Institutionen för Fysik, Chalmers Tekniska Högskola, 412 96 Göteborg, Sweden
| | - B Jonson
- Institutionen för Fysik, Chalmers Tekniska Högskola, 412 96 Göteborg, Sweden
| | - J Kahlbow
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | | | - R Kanungo
- Astronomy and Physics Department, Saint Mary's University, Halifax, Nova Scotia B3H 3C3, Canada
| | - A Kelic-Heil
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - A Knyazev
- Department of Physics, Lund University, 22100 Lund, Sweden
| | - T Kröll
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - N Kurz
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - M Labiche
- STFC Daresbury Laboratory, WA4 4AD Warrington, United Kingdom
| | - C Langer
- Goethe-Universität Frankfurt am Main, 60438 Frankfurt am Main, Germany
| | - T Le Bleis
- Physik Department E12, Technische Universität München, 85748 Garching, Germany
| | - R Lemmon
- STFC Daresbury Laboratory, WA4 4AD Warrington, United Kingdom
| | - S Lindberg
- Institutionen för Fysik, Chalmers Tekniska Högskola, 412 96 Göteborg, Sweden
| | - J Machado
- Laboratório de Instrumentação, Engenharia Biomédica e Física da Radiação (LIBPhysUNL), Departamento de Física, Faculdade de Ciências e Tecnologias, Universidade Nova de Lisboa, 2829-516 Monte da Caparica, Portugal
| | - J Marganiec
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
- ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - A Movsesyan
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - E Nacher
- Instituto de Estructura de la Materia, CSIC, Serrano 113 bis, 28006 Madrid, Spain
| | - M Najafi
- KVI-CART, University of Groningen, Zernikelaan 25, 9747 AA Groningen, The Netherlands
| | - T Nilsson
- Institutionen för Fysik, Chalmers Tekniska Högskola, 412 96 Göteborg, Sweden
| | - C Nociforo
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - S Paschalis
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- Department of Physics, University of York, Heslington, York YO10 5DD, United Kingdom
| | - A Perea
- Instituto de Estructura de la Materia, CSIC, Serrano 113 bis, 28006 Madrid, Spain
| | - M Petri
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- Department of Physics, University of York, Heslington, York YO10 5DD, United Kingdom
| | - S Pietri
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - R Plag
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - R Reifarth
- Goethe-Universität Frankfurt am Main, 60438 Frankfurt am Main, Germany
| | - G Ribeiro
- Instituto de Estructura de la Materia, CSIC, Serrano 113 bis, 28006 Madrid, Spain
| | - C Rigollet
- KVI-CART, University of Groningen, Zernikelaan 25, 9747 AA Groningen, The Netherlands
| | - M Röder
- Helmholtz-Zentrum Dresden-Rossendorf, 01328, Dresden, Germany
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, 01069 Dresden, Germany
| | - D Rossi
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - D Savran
- ExtreMe Matter Institute EMMI, GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - H Scheit
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - H Simon
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - I Syndikus
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - J T Taylor
- Oliver Lodge Laboratory, University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - O Tengblad
- Instituto de Estructura de la Materia, CSIC, Serrano 113 bis, 28006 Madrid, Spain
| | - R Thies
- Institutionen för Fysik, Chalmers Tekniska Högskola, 412 96 Göteborg, Sweden
| | - Y Togano
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - P Velho
- Laboratório de Instrumentação e Física Experimental de Partículas-LIP, 1000-149 Lisbon, Portugal
| | - V Volkov
- NRC Kurchatov Institute, Ru-123182 Moscow, Russia
| | - A Wagner
- Helmholtz-Zentrum Dresden-Rossendorf, 01328, Dresden, Germany
| | - H Weick
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - C Wheldon
- School of Physics and Astronomy, University of Birmingham, Birmingham B15 2TT, United Kingdom
| | - G Wilson
- Department of Physics, University of Surrey, Guildford GU2 7XH, United Kingdom
| | - J S Winfield
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - P Woods
- School of Physics and Astronomy, University of Edinburgh, Edinburgh EH9 3JZ, United Kingdom
| | - D Yakorev
- Helmholtz-Zentrum Dresden-Rossendorf, 01328, Dresden, Germany
| | - M Zhukov
- Institutionen för Fysik, Chalmers Tekniska Högskola, 412 96 Göteborg, Sweden
| | - A Zilges
- Institut für Kernphysik, Universität zu Köln, 50937 Köln, Germany
| | - K Zuber
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, 01069 Dresden, Germany
| |
Collapse
|
47
|
Kluess HG, Noppeney T, Gerlach H, Braunbeck W, Ehresmann U, Fischer R, Hermanns HJ, Langer C, Nüllen H, Salzmann G, Schimmelpfennig L. Leitlinie zur Diagnostik und Therapie des Krampfaderleidens. Phlebologie 2018. [DOI: 10.1055/s-0038-1638998] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Leitlinien sind systematisch erarbeitete Empfehlungen, um den Arzt in Klinik und Praxis bei Entscheidungen über eine angemessene Versorgung des Patienten im Rahmen spezi-fischer klinischer Umstände zu unterstützen. Leitlinien gelten für Standardsituationen und berücksichtigen die aktuellen, zu den entsprechenden Fragestellungen zur Verfügung stehenden wissenschaftlichen Erkenntnisse. Leitlinien bedürfen der ständigen Überprüfung und eventuell der Änderung auf dem Boden des wissenschaftlichen Erkenntnisstandes und der Praktikabilität in der tägli-chen Praxis. Durch die Leitlinien soll die Methodenfreiheit des Arztes nicht eingeschränkt werden. Ihre Beachtung garantiert nicht in jedem Fall den diagnostischen und therapeutischen Erfolg. Leitlinien erheben keinen Anspruch auf Vollständigkeit. Die Entscheidung über die Angemessenheit der zu ergreifenden Maßnahmen trifft der Arzt unter Berücksichtigung der individuellen Problematik.
Collapse
|
48
|
Chen X, Yang Y, Berger I, Khalid U, Patel A, Cai J, Farwell MD, Langer C, Aggarwal C, Albelda SM, Katz SI. Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging. Oncotarget 2018; 8:24213-24223. [PMID: 27655645 PMCID: PMC5421841 DOI: 10.18632/oncotarget.12085] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2016] [Accepted: 07/13/2016] [Indexed: 11/25/2022] Open
Abstract
Inhibition of thymidylate synthase (TS) results in a transient flare in DNA thymidine salvage pathway activity measurable with FLT ([18F]thymidine)-positron emission tomography (PET). Here we characterize this imaging strategy for potential clinical translation in non-small cell lung cancer (NSCLC). Since pemetrexed acts by inhibiting TS, we defined the kinetics of increases in thymidine salvage pathway mediated by TS inhibition following treatment with pemetrexed in vitro. Next, using a mouse model of NSCLC, we validated the kinetics of the pemetrexed-mediated flare in thymidine salvage pathway activity in vivo using FLT-PET imaging. Finally, we translated our findings into a proof-of-principle clinical trial of FLT-PET in a human NSCLC patient. In NSCLC cells in vitro, we identified a burst in pemetrexed-mediated thymidine salvage pathway activity, assessed by 3H-thymidine assays, thymidine kinase 1 (TK1) expression, and equilibrative nucleoside transporter 1 (ENT1) mobilization to the cell membrane, that peaked at 2hrs. This 2hr time-point was also optimal for FLT-PET imaging of pemetrexed-mediated TS inhibition in murine xenograft tumors and was demonstrated to be feasible in a NSCLC patient. FLT-PET imaging of pemetrexed-induced TS inhibition is optimal at 2hrs from therapy start; this timing is feasible in human clinical trials.
Collapse
Affiliation(s)
- Xiao Chen
- Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.,Department of Radiology, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, China
| | - Yizeng Yang
- Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Ian Berger
- Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Urooj Khalid
- Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Akash Patel
- Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Jenny Cai
- Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Michael D Farwell
- Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Corey Langer
- Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Charu Aggarwal
- Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Steven M Albelda
- Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Sharyn I Katz
- Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| |
Collapse
|
49
|
Griesinger F, Bennouna J, de Castro Carpeno J, Dingemans AM, Grossi F, Langer C, Ohe Y, Syrigos K, Thatcher N, Das-Gupta A, Donica M, Smoljanovic V, Gridelli C. Efficacy and safety results from AvaALL: an open-label, randomized phase III trial of standard of care (SOC) with or without continuous bevacizumab (Bev) treatment beyond progression (PD) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) progressing after first-line Bev and chemotherapy (chemo). Pneumologie 2018. [DOI: 10.1055/s-0037-1619221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- F Griesinger
- Department of Hematology and Oncology, University Hospital, Pius-Hospital Oldenburg
| | - J Bennouna
- Institut de Cancérologie de L'ouest, Nantes
| | - J de Castro Carpeno
- Translational Oncology Unit at Medical Oncology Division; Hospital Universitario La Paz; Idipaz
| | - AM Dingemans
- Department of Pulmonology; Maastricht University Medical Center
| | - F Grossi
- Lung Cancer Unit, National Institute for Cancer Research, Genova, Italien
| | - C Langer
- Thoracic Oncology Unit; Abramson Cancer Center; University of Pennsylvania, Philadelphia
| | - Y Ohe
- National Cancer Center Hospital, Tokyo
| | - K Syrigos
- Athens Medical Center; National & Kapodistrian University of Athens Medical School
| | | | | | | | | | - C Gridelli
- Division of Medical Oncology; S.G. Moscati Hospital, Avellino, Italien
| |
Collapse
|
50
|
Atar L, Paschalis S, Barbieri C, Bertulani CA, Díaz Fernández P, Holl M, Najafi MA, Panin V, Alvarez-Pol H, Aumann T, Avdeichikov V, Beceiro-Novo S, Bemmerer D, Benlliure J, Boillos JM, Boretzky K, Borge MJG, Caamaño M, Caesar C, Casarejos E, Catford W, Cederkall J, Chartier M, Chulkov L, Cortina-Gil D, Cravo E, Crespo R, Dillmann I, Elekes Z, Enders J, Ershova O, Estrade A, Farinon F, Fraile LM, Freer M, Galaviz Redondo D, Geissel H, Gernhäuser R, Golubev P, Göbel K, Hagdahl J, Heftrich T, Heil M, Heine M, Heinz A, Henriques A, Hufnagel A, Ignatov A, Johansson HT, Jonson B, Kahlbow J, Kalantar-Nayestanaki N, Kanungo R, Kelic-Heil A, Knyazev A, Kröll T, Kurz N, Labiche M, Langer C, Le Bleis T, Lemmon R, Lindberg S, Machado J, Marganiec-Gałązka J, Movsesyan A, Nacher E, Nikolskii EY, Nilsson T, Nociforo C, Perea A, Petri M, Pietri S, Plag R, Reifarth R, Ribeiro G, Rigollet C, Rossi DM, Röder M, Savran D, Scheit H, Simon H, Sorlin O, Syndikus I, Taylor JT, Tengblad O, Thies R, Togano Y, Vandebrouck M, Velho P, Volkov V, Wagner A, Wamers F, Weick H, Wheldon C, Wilson GL, Winfield JS, Woods P, Yakorev D, Zhukov M, Zilges A, Zuber K. Quasifree (p, 2p) Reactions on Oxygen Isotopes: Observation of Isospin Independence of the Reduced Single-Particle Strength. Phys Rev Lett 2018; 120:052501. [PMID: 29481189 DOI: 10.1103/physrevlett.120.052501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/14/2017] [Revised: 11/08/2017] [Indexed: 06/08/2023]
Abstract
Quasifree one-proton knockout reactions have been employed in inverse kinematics for a systematic study of the structure of stable and exotic oxygen isotopes at the R^{3}B/LAND setup with incident beam energies in the range of 300-450 MeV/u. The oxygen isotopic chain offers a large variation of separation energies that allows for a quantitative understanding of single-particle strength with changing isospin asymmetry. Quasifree knockout reactions provide a complementary approach to intermediate-energy one-nucleon removal reactions. Inclusive cross sections for quasifree knockout reactions of the type ^{A}O(p,2p)^{A-1}N have been determined and compared to calculations based on the eikonal reaction theory. The reduction factors for the single-particle strength with respect to the independent-particle model were obtained and compared to state-of-the-art ab initio predictions. The results do not show any significant dependence on proton-neutron asymmetry.
Collapse
Affiliation(s)
- L Atar
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
| | - S Paschalis
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- Department of Physics, University of York, York YO10 5DD, United Kingdom
| | - C Barbieri
- Department of Physics, University of Surrey, Guildford GU2 7XH, United Kingdom
| | - C A Bertulani
- Texas A&M University-Commerce, 75428 Commerce, Texas, United States of America
| | - P Díaz Fernández
- Departamento de Física de Partículas, Universidade de Santiago de Compostela, 15706 Santiago de Compostela, Spain
| | - M Holl
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - M A Najafi
- KVI-CART, University of Groningen, Zernikelaan 25, 9747 AA Groningen, Netherlands
| | - V Panin
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- RIKEN, Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, 351-0198 Wako, Saitama, Japan
| | - H Alvarez-Pol
- Departamento de Física de Partículas, Universidade de Santiago de Compostela, 15706 Santiago de Compostela, Spain
| | - T Aumann
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
| | - V Avdeichikov
- Department of Physics, Lund University, 22100 Lund, Sweden
| | - S Beceiro-Novo
- Departamento de Física de Partículas, Universidade de Santiago de Compostela, 15706 Santiago de Compostela, Spain
| | - D Bemmerer
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiation Physics, P.O.B. 510119, 01314 Dresden, Germany
| | - J Benlliure
- Departamento de Física de Partículas, Universidade de Santiago de Compostela, 15706 Santiago de Compostela, Spain
| | - J M Boillos
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
- Departamento de Física de Partículas, Universidade de Santiago de Compostela, 15706 Santiago de Compostela, Spain
| | - K Boretzky
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
| | - M J G Borge
- Instituto de Estructura de la Materia, CSIC, E-28006 Madrid, Spain
| | - M Caamaño
- Departamento de Física de Partículas, Universidade de Santiago de Compostela, 15706 Santiago de Compostela, Spain
| | - C Caesar
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
| | | | - W Catford
- Department of Physics, University of Surrey, Guildford GU2 7XH, United Kingdom
| | - J Cederkall
- Department of Physics, Lund University, 22100 Lund, Sweden
| | - M Chartier
- University of Liverpool, L69 3BX Liverpool, United Kingdom
| | - L Chulkov
- NRC Kurchatov Institute, place Akademika Kurchatova, Moscow 123182, Russia
| | - D Cortina-Gil
- Departamento de Física de Partículas, Universidade de Santiago de Compostela, 15706 Santiago de Compostela, Spain
| | - E Cravo
- Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisboa, Portugal
| | - R Crespo
- Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisboa, Portugal
| | - I Dillmann
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
- Justus-Liebig-Universität Gießen, 35392 Gießen, Germany
| | - Z Elekes
- ATOMKI Debrecen, Bem tér 18/c, 4026 Debrecen, Hungary
| | - J Enders
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - O Ershova
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
| | - A Estrade
- University of Edinburgh, EH8 9YL Edinburgh, United Kingdom
| | - F Farinon
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - L M Fraile
- Grupo de Física Nuclear & IPARCOS, Universidad Complutense de Madrid, 28040 Madrid, Spain
| | - M Freer
- University of Birmingham, B15 2TT Birmingham, United Kingdom
| | - D Galaviz Redondo
- Nuclear Physics Center, University of Lisbon, 1649-003 Lisboa, Portugal
| | - H Geissel
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
- Justus-Liebig-Universität Gießen, 35392 Gießen, Germany
| | - R Gernhäuser
- Technische Universität München, James-Franck-Straße 1, 85748 Garching, Germany
| | - P Golubev
- Department of Physics, Lund University, 22100 Lund, Sweden
| | - K Göbel
- Goethe-Universität Frankfurt, Max-von-Laue Straße 1, 60438 Frankfurt am Main, Germany
| | - J Hagdahl
- Chalmers University of Technology, Kemivägen 9, 412 96 Göteborg, Sweden
| | - T Heftrich
- Goethe-Universität Frankfurt, Max-von-Laue Straße 1, 60438 Frankfurt am Main, Germany
| | - M Heil
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
| | - M Heine
- IPHC-CNRS/Université de Strasbourg, 67037 Strasbourg, France
| | - A Heinz
- Chalmers University of Technology, Kemivägen 9, 412 96 Göteborg, Sweden
| | - A Henriques
- Nuclear Physics Center, University of Lisbon, 1649-003 Lisboa, Portugal
| | - A Hufnagel
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - A Ignatov
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - H T Johansson
- Chalmers University of Technology, Kemivägen 9, 412 96 Göteborg, Sweden
| | - B Jonson
- Chalmers University of Technology, Kemivägen 9, 412 96 Göteborg, Sweden
| | - J Kahlbow
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | | | - R Kanungo
- Saint Mary's University, 923 Robie Street, B3H 3C3 Halifax, Nova Scotia, Canada
| | - A Kelic-Heil
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
| | - A Knyazev
- Department of Physics, Lund University, 22100 Lund, Sweden
| | - T Kröll
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - N Kurz
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
| | - M Labiche
- Science and Technology Facilities Council-Daresbury Laboratory, WA4 4AD Warrington, United Kingdom
| | - C Langer
- Goethe-Universität Frankfurt, Max-von-Laue Straße 1, 60438 Frankfurt am Main, Germany
| | - T Le Bleis
- Technische Universität München, James-Franck-Straße 1, 85748 Garching, Germany
| | - R Lemmon
- Science and Technology Facilities Council-Daresbury Laboratory, WA4 4AD Warrington, United Kingdom
| | - S Lindberg
- Chalmers University of Technology, Kemivägen 9, 412 96 Göteborg, Sweden
| | - J Machado
- Nuclear Physics Center, University of Lisbon, 1649-003 Lisboa, Portugal
| | - J Marganiec-Gałązka
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
- Extreme Matter Institute, GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
| | - A Movsesyan
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - E Nacher
- Instituto de Estructura de la Materia, CSIC, E-28006 Madrid, Spain
| | - E Y Nikolskii
- NRC Kurchatov Institute, place Akademika Kurchatova, Moscow 123182, Russia
| | - T Nilsson
- Chalmers University of Technology, Kemivägen 9, 412 96 Göteborg, Sweden
| | - C Nociforo
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
| | - A Perea
- Instituto de Estructura de la Materia, CSIC, E-28006 Madrid, Spain
| | - M Petri
- Department of Physics, University of York, York YO10 5DD, United Kingdom
| | - S Pietri
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
| | - R Plag
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
| | - R Reifarth
- Goethe-Universität Frankfurt, Max-von-Laue Straße 1, 60438 Frankfurt am Main, Germany
| | - G Ribeiro
- Instituto de Estructura de la Materia, CSIC, E-28006 Madrid, Spain
| | - C Rigollet
- KVI-CART, University of Groningen, Zernikelaan 25, 9747 AA Groningen, Netherlands
| | - D M Rossi
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
| | - M Röder
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiation Physics, P.O.B. 510119, 01314 Dresden, Germany
- Technische Universität Dresden, Institut für Kern- und Teilchenphysik, Zellescher Weg 19, 01069 Dresden, Germany
| | - D Savran
- Extreme Matter Institute, GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
| | - H Scheit
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - H Simon
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
| | - O Sorlin
- GANIL, Boulevard Henri Becquerel, 14076 Caen, France
| | - I Syndikus
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
| | - J T Taylor
- University of Liverpool, L69 3BX Liverpool, United Kingdom
| | - O Tengblad
- Instituto de Estructura de la Materia, CSIC, E-28006 Madrid, Spain
| | - R Thies
- Chalmers University of Technology, Kemivägen 9, 412 96 Göteborg, Sweden
| | - Y Togano
- RIKEN, Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, 351-0198 Wako, Saitama, Japan
| | - M Vandebrouck
- GANIL, Boulevard Henri Becquerel, 14076 Caen, France
| | - P Velho
- Nuclear Physics Center, University of Lisbon, 1649-003 Lisboa, Portugal
| | - V Volkov
- NRC Kurchatov Institute, place Akademika Kurchatova, Moscow 123182, Russia
| | - A Wagner
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiation Physics, P.O.B. 510119, 01314 Dresden, Germany
| | - F Wamers
- Institut für Kernphysik, Technische Universität Darmstadt, 64289 Darmstadt, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
| | - H Weick
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
| | - C Wheldon
- University of Birmingham, B15 2TT Birmingham, United Kingdom
| | - G L Wilson
- University of Surrey, GU2 7XH Surrey, United Kingdom
| | - J S Winfield
- GSI Helmholtzzentrum für Schwerionenforschung, Planckstraße 1, 64291 Darmstadt, Germany
- Justus-Liebig-Universität Gießen, 35392 Gießen, Germany
| | - P Woods
- University of Edinburgh, EH8 9YL Edinburgh, United Kingdom
| | - D Yakorev
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiation Physics, P.O.B. 510119, 01314 Dresden, Germany
| | - M Zhukov
- Chalmers University of Technology, Kemivägen 9, 412 96 Göteborg, Sweden
| | - A Zilges
- Universität zu Köln, Institut für Kernphysik, Zülpicher Straße 77, 50937 Köln, Germany
| | - K Zuber
- Technische Universität Dresden, Institut für Kern- und Teilchenphysik, Zellescher Weg 19, 01069 Dresden, Germany
| |
Collapse
|